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Abstract 
Obesity and its resulting co-morbidities place a huge burden on the Australian 
healthcare system and economy. Alterations to the body’s normal circadian rhythm 
increase the risk of developing obesity and metabolic dysfunction. Like most 
metabolically active tissues, circadian rhythm has been observed in brown adipose 
tissue (BAT) a site of thermogenesis, whereby heat is released via the process of 
uncoupled respiration, involving uncoupling protein-1 (UCP-1). Activation of 
thermogenesis in BAT has potential to treat metabolic dysfunction. We have previously 
shown that ongoing exposure to low dose ultraviolet radiation (UVR) curbed weight 
gain and limited metabolic dysfunction in mice fed a high fat diet through mechanisms 
involving skin release of nitric oxide(1). We hypothesised that regular exposure to low 
dose UVR (1 kJ/m2 UVB radiation, twice a week) would alter the circadian rhythm of 
thermogenesis in BAT of mice fed a high fat diet, through skin release of nitric oxide.  
The circadian rhythm of thermogenesis in BAT was examined by monitoring expression 
of the UCP-1, using UCP-1 luciferase transgenic (‘thermomouse’, FVB/NJ background, 
n=12/treatment) male mice. In this mouse, UCP-1 expression in the interscapular BAT 
(iBAT) was tracked by monitoring bioluminescence following their injection with the 
substrate luciferin. The circadian rhythm analyses involved measuring UCP-1 
bioluminescence in iBAT, as well as blood glucose and and interscapular skin 
temperature at 4-6 hourly intervals over a 28 hours time-course. This was done at 
baseline, and after 6 and 12 weeks of feeding mice a high or low fat diet..  
There were four treatment groups in this 12-week study: 
1. Mice fed a low-fat diet, and mock-irradiated (n=20);
2. Mice fed a high fat diet, and mock-irradiated (n=20);
iv
3. Mice fed a high fat diet, and exposed twice a week to low dose UVR (1 kJ/m2)
(n=20); or,
4. Mice fed a high fat diet and exposed twice a week to low dose UVR (1 kJ/m2)
and topically treated with the nitric oxide scavenger, cPTIO (1 mM) (n=20).
Signs of adiposity and metabolic dysfunction were also monitored by weighing mice, 
performing glucose and insulin tolerance tests, and measuring levels of liver steatosis 
via histopathology.  
Weak trends of circadian rhythmicity was noted in interscapular skin temperature 
during week 12. Ongoing UVR exposure to mice fed a high fat diet had moderately 
altered the level of UCP-1 expression in interscapular brown adipose tissue. Ongoing 
UVR exposure seemed to increase the potential of metabolic buffering in response to 
the high fat diet, and thus reducing the need for diet induced thermogenesis. More so, 
ongoing UVR suppressed the development of fatty liver disease in mice fed a high fat 
diet. The outcome of this study provides evidence that UVR exposure may suppress 
need for metabolic compensation in terms of diet-induced thermogenesis. The 
suppressive effects of UVR on signs of adiposity (e.g. hepatic steatosis and reduced 
WAT weights) were not linked with increased rates of thermogenesis in iBAT, in the 
absence of a circadian rhythm of UCP-1 expression in iBAT). And so if it is not the 
thermogenesis in BAT, it is important to examine the effects of UVR on other metabolic 
pathways and tissues as future focus. 
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Obesity is the uncontrolled and unhealthy accumulation of excess white adipose tissue. 
It is traditionally theorised to result from an imbalance between energy intake and 
energy expenditure; however, environmental, socio-cultural factors and genetic 
predisposition may play an important role in its development. Obesity is linked with an 
increased risk of developing serious health disorders, like cardiovascular disease 
(CVD), insulin resistance and type-2 diabetes(2-4). With the ongoing steady increase of 
obesity prevalence in many locations around the world, novel treatments to help curb 
weight gain and prevent metabolic dysfunction are needed. 
 
Metabolically active tissues are regulated by a circadian rhythm. Moreover, any 
disruption in the body’s circadian rhythm alters normal metabolic function(5). 
Disruptions in the normal circadian rhythm are associated with an increased risk of 
metabolic dysfunction(5,6). One example of a metabolically active tissue, which 
displays circadian rhythm is brown adipose tissue (BAT). This tissue plays an important 
role in regulating energy balance and body weight(7) through thermogenesis, in which 
energy stores are used, and heat is produced via uncoupled respiration(8-10). Activating 
thermogenesis in BAT could increase energy expenditure(11) and has potential to curb 
the development of metabolic dysfunction caused by energy imbalance.  
 
Previous studies in our laboratory have observed that ongoing exposure to low dose 
(1kJ/m2 UVB) ultraviolet radiation (UVR) suppressed weight gain and signs of 
metabolic dysfunction in mice fed a high fat diet(1,12). Some of the beneficial effects of 
UVR were identified to occur through the release of nitric oxide from irradiated 
skin(1,12). In this study we investigated whether ongoing exposure of mice fed a high 
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fat diet to low dose UVR altered the circadian rhythm of thermogenesis in BAT. We 
also tested the capacity of UVR-induced nitric oxide to modulate thermogenesis in 
BAT, by applying a nitric oxide scavenger to the shaved dorsal skin of mice following 
exposure to UVR.  
 
1.1 Obesity and metabolic dysfunction 
 
1.1.1 Defining obesity 
Obesity is the abnormal and/or excessive accumulation of fat in the form of white 
adipose tissue (WAT) that presents major health risks(13). Obesity is mostly diagnosed 
by measuring an individual’s body mass index (BMI, kg/m2), or waist 
circumference(13,14). Clinically, individuals with BMI of greater than or equal to 30 
kg/m2 are classified as obese while those with BMI between 25 to 30 kg/m2 are 
overweight(15,16). Controversies exist around using BMI to clinically define obesity, 
as it does not account for variations in muscle mass or body fat distribution(17,18). 
Waist circumference is often regarded as a better determinant of obesity and overweight 
than BMI, as it is a better marker for total body adiposity(17-19). Increased BMI and 
waist circumference are linked to poor health outcomes(20,21) such as: CVD, type-2 
diabetes, metabolic syndrome, hypertension and non-alcoholic fatty liver disease 
(NAFLD)(22-25). Obesity also increases the risk for mental disorders such as 






1.1.2 Obesity prevalence, costs and current treatment 
 
 
Obesity is a major epidemic worldwide. It increases the risk for mortality and 
morbidity(27) and poses a large threat to global economic and healthcare systems(28). 
In 2014-15, more than 28% of the Australian adult population were obese and a further 
35% of Australian adults were overweight(30). One in four Australian children (2-17 
years of age) were overweight or obese in 2014-15(13,28). Globally, obesity rates are 
expected to continue to increase (Figure 1.1)(31) and in Australian, the prevalence of 
obesity in adults rose from 19% in 1995 to 28% in 2015(28). Obesity was estimated to 
be responsible for approximately 7% of the total health burden in Australia, and cost the 
economy AUD8.6 billion in 2011-12(13). Costs are estimated to be even greater when 
combined with those generated by co-morbidities of obesity, such as CVD and type-2 
diabetes (>AUD 16 billion in 2011-12)(32).  
 
 
Figure 1.1 Projected rates of obesity in countries around the world till 2030. The projections 
show a steady increase in obesity prevalence in many countries around the world, with data 
for nine countries shown here. Adapted from OECD 2017(31). 
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Current strategies to curb obesity and its metabolic consequences include improving 
diet (reducing caloric intake)(33,34), and increasing physical activity(35,36). Other 
treatments include invasive surgeries (bariatric surgery), certain drugs like 
bupropion/naltrexone (not available in Australia) and phentermine (available and used 
in Australia)(37-39). With the increasing prevalence (and associated health and 
economic costs) of obesity, current strategies to curb its development and the 
progression from overweight to obesity are not effective, and that new strategies to 
tackle this global issue are much needed.  
 
1.1.2.1 Causes of obesity 
Obesity is traditionally thought to arise from an ongoing mismatch between excessive 
energy intake and inadequate energy expenditure(40,41), through poor diet (excessive 
sugar and fat consumption), inadequate physical activity and a sedentary 
lifestyle(13,42,43). However, genetic predisposition(43), and other environmental(44) 
and social factors(45) may also contribute towards the development of obesity. With 
easy access to energy-rich foods, and our increasing sedentary (and indoor) lifestyles, it 
is easy for humans living in many countries around the world to overconsume and 
expend less energy, tipping the energy balance towards weight gain(45,46). 
 
1.1.2.1.1 Dietary imbalance  
Unhealthy eating patterns and the consumption of highly processed, high energy and 
salty foods and high sugar beverages contribute to the excessive intake of sugar, 
saturated fats and trans-fatty acids, which are important determinants of increased 
energy consumption(48-50). Sugary foods and drinks consumed by children are likely 
to play an integral role in the development of childhood obesity(34,47). 
Epidemiological studies have demonstrated direct linear relationships between dietary 
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fat and sugar intake and development of obesity(25). Human studies have reported that 
eating a high fat diet (≥30% of total caloric intake derived from fat) is significantly 
associated with obesity development(47,48,51,52). Experimentally, feeding rodents 
diets high in fat (and sugar) increased weight gain, compared to rodents fed a low fat 
(and sugar) diet(53). Typically, diet-induced obesity can be modelled in rodents by 
feeding rats or mice diets which have 30-78% of total caloric intake derived from 
fat(25,54). Animal models of diet-induced obesity have been widely utilised to control 
variables that are difficult to measure in humans, such as food intake, physical activity, 
and environmental exposures (e.g. sunlight and temperature)(1,54). For example, under-
reporting of dietary intake is a major source of bias in human studies(25,55).  
 
1.1.2.1.2 Factors that govern energy expenditure  
Daily energy expenditure is determined by three factors: basal metabolic rate, 
thermogenesis (induced by diet or cold) and the energy cost of physical activity(56). 
Basal metabolic rate is the energy used to maintain vital body processes while at rest. It 
is genetically determined and is reduced in individuals with obesity(57). Thermogenesis 
is the energy expended above the basal metabolic rate. Two main factors contribute to 
thermogenesis: food intake and cold exposure. These elicit diet-induced thermogenesis 
(DIT) and non-shivering thermogenesis, respectively(56,58). DIT is affected by 
consuming a high fat diet and is dysregulated in obese individuals(56,59-61) (see 
Section 1.2.2.4 for details). Finally, physical activity, including sports, recreation and 
incidental activity such as walking and house-work contribute significantly towards 
energy expenditure(3) and have positive health impacts in maintaining fitness, heart 
health, reducing body fat and the likelihood of gaining weight(13). Conversely, low or 
zero physical activity combined with a sedentary lifestyle significantly contributes 
towards the development of obesity(62). Australian adults who lead a sedentary lifestyle 
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(with an average of 34 hours per week sitting at leisure) are more likely to be obese or 
overweight, than more active individuals(13,63-65). 
1.1.2.1.3 Genetic predisposition 
Human genome-wide studies have identified that the genetic predisposition contributes 
towards the development of obesity. Genetic factors may account for 40-90% of 
population-wide variation in BMI(66,67). Identified genes are involved in processes 
that alter the energy balance equation regarding both energy intake and expenditure(68). 
The fat mass and obesity-associated protein or alpha-ketoglutarate-dependent 
dioxygenase gene (FTO gene) is widely accepted as a contributor to polygenic obesity, 
and may control feeding behaviour and energy expenditure(69). Deletion or the 
uniparental (from maternal end) disomy of paternal chromosome 15 leads to Prader-
Willi syndrome, causing lack of satiety(70), and eventually obesity and type-2 
diabetes(71). A genetic predisposition for obesity may be more common in people of 
certain ethnic groups. For example, BMI amongst individuals of Oceanic and Pacific 
(particularly Samoans) island ethnicity was strongly influenced by p.Arg457Gln, a 
missense variant in the CREBRF gene(72-74).  
 
Single gene mutations contribute towards the development of obesity and type-2 
diabetes in rodents. In transgenic mouse models such as the ob/ob mutant mouse, a 
single base spontaneous mutation in the ob gene inhibited bioactive leptin (reduces 
satiety, see Section 1.2.1.1.1) and increased weight gain and signs of obesity(75). The 
ob/ob mouse strain exhibited hyperphagia (excessive eating), insulin resistance, 
hyperlipidaemia, excessive adipose tissue, morbid obesity and impaired reproductive 
behaviour(75). Another strain of mouse exhibiting a similar phenotype is the db/db 
mouse strain, which has a mutation in the leptin receptor gene (lep)(76). Studies 
conducted in the C57Bl/6 mice have reported that this strain develops late onset obesity 
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regardless of diet(77,78). These effects are not observed in all inbred mouse strains 
suggesting a role for genetic background in determining the susceptibility for weight 
gain and the development of metabolic dysfunction. For example, mice of FVB/NJ 
strain are less susceptible to obesity and type-2 diabetes development than C57B1/6 
mice when fed a high fat diet(75,79).  
 
1.1.2.1.3 Epigenetic variation 
Epigenetic variation, including altered DNA methylation profile, modifications to 
histones and microRNA expression, are associated with impaired metabolic function in 
organs (especially liver and adipose tissue) responsible for maintaining glucose and 
lipid homeostasis(80,81). These forms of epigenetic variation have been identified in 
immune cells of individuals clinically diagnosed with obesity and type-2 
diabetes(82,83). Widespread variations in DNA methylation across the genome are 
positively associated with increased BMI(84), with methylation identified in genes 
involved in lipoprotein metabolism, substrate transport and inflammation(85). Variation 
in methylation activation status between generations suggests that epigenetic changes 
may contribute directly towards the development of obesity(87). The specific epigenetic 
mechanisms that contribute towards obesity are still largely unknown; however, results 
of studies done in animal models and people with rare syndromes suggest that it is 
likely that genetics and environment increase the risk for obesity through epigenetic 
modification of the genome(87). 
 
1.1.2.1.4 Developmental origins 
The thrifty phenotype hypothesis (also known as the Barker hypothesis) suggests that 
adverse outcome(s) in the developing foetus are caused due to a range of insults 
experienced in the in utero environment. The Barker hypothesis originally highlighted 
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the relationship between low birth weight and an obese adult phenotype(88,89). There is 
also now significant evidence to support that high birth weight influences long-term 
outcomes, and increases the likelihood of obesity development(90). There has also been 
significant association between maternal obesity and weight gain during pregnancy with 
an increased risk of childhood obesity, as observed in human epidemiological studies 
and rodent models(91-93). In mice and humans, epigenetic changes introduced during 
early development have been linked increased weight gain in obese mothers who have 
obese offspring(92,94). 
 
1.1.2.1.5 Environmental exposures 
There may be a range of external environmental exposures that could contribute 
towards the development of obesity and metabolic dysfunction including infection, 
heavy metals and synthetic environmental pollutants(44). Infection with adenovirus 36 
is positively associated with the development of obesity in humans and monkeys(95-
97). The environmental ‘obesogen’ hypothesis states that there is a positive relationship 
between chemical exposure and weight gain(44,100). Exposure to many heavy metals 
such as cadmium, mercury, barium and thallium may increase the risk of developing 
hyperglycaemia, type-2 diabetes, larger waist circumference and obesity(44,99). Some 
chemical/plastic-derived ‘obesogens’ (e.g. Bisphenol A, phthalates) could also 
contribute towards obesity via pathways that modulate satiety and WAT 
morphology(101). More recently, animal studies from our laboratory(1,102) and other 
studies in humans have suggested there may be protective effects of exposure to low 
dose ultraviolet radiation (UVR) or sunlight in reducing weight gain and curbing 
metabolic dysfunction (see Section 1.4.5.2).  
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1.1.3 Co-morbidities associated with obesity 
Obesity is associated with a range of chronic health conditions including disorders that 
adversely affect metabolism, such as: insulin resistance, glucose intolerance, 
dyslipidaemia, type-2 diabetes, metabolic syndrome and NAFLD, as well as 
cardiovascular problems such as hypertension. Other unfavourable health outcomes of 
obesity include: certain types of cancer (e.g. oesophageal, pancreatic, thyroid), sleep 
apnoea, chronic back pain, osteoarthritis, and depression(41,103-105). These conditions 
contribute to the increased rates of mortality and morbidity experienced by individuals 
with obesity, compared to non-obese individuals(41). In a study published in 2009, 
having a BMI of 30-35 kg/m2 reduced median life expectancy by 2-4 years, while 
having a BMI >35 kg/m2, reduced life expectancy by 8-10 years(2,106). Discussed 
below are some of the major metabolic co-morbidities associated with obesity. 
 
1.1.3.1 Insulin intolerance and glucose tolerance  
Elevated fasting blood glucose levels, reduced glucose clearance rates and insulin 
resistance are more likely to develop in people with obesity(4,24,107). Insulin is 
released by beta cells located in the islets of Langerhans of the pancreas(108). Insulin is 
a peptide hormone responsible for maintaining and regulating blood glucose 
homeostasis, protein and lipid metabolism(41,109,110). Insulin resistance occurs when 
target cells fail to respond normally when exposed to insulin, and progressively results 
in an impaired sensitivity to insulin-mediated glucose disposal. Insulin resistance 
typically precedes type-2 diabetes(109,111-113). Insulin resistance in obesity and type-
2 diabetes manifests as decreased insulin-regulated glucose transport, metabolic 
dysfunction of adipocytes and impaired suppression of hepatic glucose output(114). 
Insulin resistance commonly develops in multiple cell types including hepatocytes, 
adipocytes and muscle, whereby a reduction in the insulin receptor expression in these 
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tissues has been positively correlated to insulin resistance and thus type-2 
diabetes(109,110).  
 
Glucose intolerance is a pre-diabetic state of hyperglycaemia and is associated with 
insulin resistance and an increased risk for the development of type-2 diabetes(115). 
Weight gain reduces glucose uptake by insulin-resistant muscle tissue leading to a state 
of compensatory hyperinsulinemia and increases in glucose production by the liver(24). 
When insulin resistance is hard to overcome, the risk of developing hyperglycaemia and 
type-2 diabetes increases(108).  
 
1.1.3.2 Dyslipidaemia 
Dyslipidaemia is defined as elevated concentrations of free-fatty acids (FFA) in 
blood(116). Dyslipidaemia is characterised by increased triglycerides (greater than 160 
mg/dL), decreased high-density lipoprotein (less than 50 mg/dL), and abnormal low-
density lipoprotein concentrations in blood (117,118). Dyslipidaemia contributes 
towards other metabolic dysfunction, including insulin resistance, atherosclerosis 
(narrowing of arteries due to plaque build-up)(119), CVD(117) and NAFLD(120). 
Excessive adipose tissue expansion, which occurs during obesity, results in a release of 
pro-inflammatory cytokines (see Section 1.2.1.1.3) from adipose tissue, stimulating 
lipolysis and secretion of FFAs into blood(24,121). FFAs reduces glucose uptake and 
prevents the suppression of glucose production in the liver usually regulated by 
insulin(113). Furthermore, dyslipidaemia within the pancreatic islets is lipotoxic and is 
associated with impaired secretion of insulin and the development of type-2 
diabetes(24). Circulating FFAs like triglycerides are significantly elevated in obese and 
type-2 diabetic individuals. Increased levels of FFAs elevate risk for myocardial 
infarction, ischemic heart disease and death(122).  
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1.1.3.3 Type-2 diabetes 
Type-2 diabetes is an increasingly common metabolic disorder characterised by long-
term hyperglycaemia and insulin resistance(123,124). The development of type-2 
diabetes in individuals with obesity is complex and involves progression through 
several metabolic disorders. Circulating FFAs and adipokines (cytokines released from 
adipose tissues, Section 1.2.1.1) released from WAT (accumulated in excess), decrease 
insulin sensitivity, increasing the amount of insulin needed to control blood 
glucose(125). Insulin resistance(125) and glucose intolerance(124) (defined above in 
Section 1.1.3.1) are predictors of type-2 diabetes. A state of sustained hyperglycaemia 
occurs in individuals with type-2 diabetes, which may be asymptomatic for some, but 
for others, common symptoms include: weakness, fatigue, skin infections, slow wound 
healing, frequent urination and excessive thirst(64,124,126). The clinical manifestations 
of pre-diabetes are elevated fasting blood glucose levels, with impaired glucose 
tolerance are evident in some people with obesity(127). Animal models have been used 
to demonstrate a causal relationship between obesity and type-2 diabetes. Rodents fed 
high fat diets have an increased weight gain and develop insulin resistance and other 
signs of type-2 diabetes, compared to mice fed a standard chow or a low fat 
diet(1,4,114,128).  
 
1.1.3.4 Cardiovascular disease & hypertension  
Strong relationships between CVD, hypertension and obesity are well-established(126), 
and are likely perpetuated by endothelial dysfunction commonly observed in individuals 
with obesity(129,130). This endothelial dysfunction increases carotid artery intimal 
medial thickness and left ventricle mass(23). Increased circulation of FFAs causes 
excessive fat accumulation, which can impair endothelium-dependent vasodilation 
leading to hypertension in obese individuals(130). Endothelial resistance to insulin is 
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acquired during obesity and insulin resistance, during which the endothelium-dependent 
mechanism of vasodilation is interrupted(4,112). Hypertension can cause long-term 
problems and can put the individual at major risk of a heart failure or stroke(131). 
Lifestyle factors such as excessive body weight, and alcohol use account for up to 95% 
of hypertension(132).  
 
1.1.3.5 Non-alcoholic fatty liver disease 
There is a range of liver abnormalities associated with obesity. These are collectively 
referred to as non-alcoholic fatty liver disease (NAFLD). The most prominent 
characteristic of NAFLD is steatosis (fat accumulation in liver)(133). NAFLD can range 
from steatosis to non-alcoholic steatohepatitis (NASH), a state where steatosis is 
combined with inflammation and fibrosis(134). While the liver can be fatty without 
disturbing its normal liver function, varying insults induce the progression of steatosis 
toward NASH(134,135). The deposition of FFA in the liver can also progress the 
development of insulin resistance, promote hepatic glucose production, induce 
inflammation and dyslipidaemia, and further contribute to the development of NAFLD 
and NASH(24,44,134-137). NAFLD is associated with an increased risk of metabolic 
dysfunction, type-2 diabetes, hypertension and dyslipidaemia(138,139). Given the 
major health risks that NAFLD poses, and the prevalence of obesity, it is a major public 
health problem worldwide(133). Findings from epidemiological studies suggest that 
eating a high fat diet increases the risk of developing NAFLD(140,141). Liver 
pathology from mouse models, in which obesity is induced by feeding mice a high fat 
diet, is similar to that observed in humans with NAFLD(142).  
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1.2 Adipose tissue 
Adipocytes, or fat cells, are in loose connective tissues known as adipose tissue. 
Adipose tissues are long-term energy stores. The two major types of adipose tissues are 
white adipose tissue (WAT) and brown adipose tissue (BAT)(143-145). Pink adipose 
tissue develops in subcutaneous fat depots during pregnancy and lactation(145). A 
subtype of adipose tissue is brite – brown in white – or beige adipose tissue(144,146). 
Brite adipose tissue is often located within WAT and is characterised by increased rates 
of thermogenesis than that which is usually observed in WAT(147). While adipose 
tissue is the body’s main long-term energy storage, it has numerous other roles 
including: metabolic communication, thermoregulation, reproduction and satiety(148). 
The different types of adipose tissues differ in their functions and have different 
regulatory mechanisms. 
 
1.2.1 White adipose tissue 
WAT is composed of large white adipocytes that contain very few mitochondria. WAT 
is a storage site for energy, and is more abundant in the human body than BAT(143). 
Excessive accumulation of WAT in the body plays an important role in the development 
of obesity and obesity-related comorbidities like type-2 diabetes and NAFLD(149) (see 
Sections 1.1.3.3 and 1.1.3.5). In humans, important deposits of WAT occur in the 
subcutaneous, perirenal, pulmonary and epicardial regions(150). In rodents, WAT is 
located in the gonadal (lower abdominal) region and subcutaneously near the limbs(8). 
WAT is a storage site for FFAs and provides insulation under cold conditions(151). If 
the storage capacity of WAT is exceeded, FFAs can no longer be cleared effectively 
from circulation and this results in the accumulation of FFA in other organs such as 
skeletal muscle and liver(151). Elevated levels of FFAs cause lipotoxicity, which 
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eventually causes insulin resistance and type-2 diabetes(108). WAT releases cytokines 
known as adipokines, which exhibit important endocrine functions, as detailed below. 
 
1.2.1.1 Adipokines 
Adipokines, released by adipose tissues, play an important role in regulating metabolic 
function(24). Under ‘healthy’ conditions, WAT secretes adipokines such as leptin, and 
adiponectin(152). Obesity significantly alters the normal energy storage and endocrine 
functionality of WAT(24). Excessive accumulation of FFAs in WAT changes its 
morphology, inducing the development of crown-like structures and larger 
adipocytes(153). Excessive FFAs induce an inflammatory response (macrophage 
infiltration that form crown-like structures) in WAT to promote pro-inflammatory 
cytokine production and secretion of adipokines(143). This process can promote insulin 
resistance and thus, type-2 diabetes and obesity(153). Adipokines such as leptin and 
adiponectin, and pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumour 
necrosis factor-alpha (TNF-) have varying roles in regulating metabolic function(154).  
 
1.2.1.1.1 Leptin 
Leptin is an essential adipokine (and hormone), that regulates satiety and energy 
homeostasis by controlling appetite and managing calorie intake(155). Leptin is 
regulated through a cognate receptor in the arcuate nucleus of the hypothalamus through 
which it suppresses appetite and reduces food intake(24,156). During obesity and 
excessive weight gain, leptin resistance is observed, where the body shows an inability 





Adiponectin is an anti-diabetic adipokine hormone, which regulates lipid and glucose 
metabolism(159,160). Adiponectin attenuates inflammation in endothelia, epithelial and 
muscle cells and reduces the proliferation of adipocytes(157), and may reduce oxidative 
stress(162). Adiponectin in combination with leptin (injected interperitoneally) can 
completely reverse signs of insulin resistance and reduced the WAT weight in obese 
mice(163). Low levels of adiponectin have been associated with development of 
obesity, and metabolic disorders such as insulin resistance and type-2 diabetes(24). 
 
1.2.1.1.3 Proinflammatory cytokines  
Cytokines are pleiotropic proteins responsible for the regulation of immunological and 
non-immunological processes(164-168). Typically, pro-inflammatory cytokines 
augment the inflammatory cascade by recruiting leukocytes, while anti-inflammatory 
cytokines down-regulate inflammatory response(165). Excessive weight gain is 
associated with increased expression of pro-inflammatory cytokines by WAT, 
contributing towards the development a chronic low-grade inflammation, which 
exacerbates the development of metabolic dysfunction(24,124,154,168-172). It is 
theorised that when WAT deposits expand in size, hypoxia occurs causing inflammation 
(172,173). Major WAT-derived inflammatory mediators such as IL-6 and TNF- 
induce a range of acute-phase reactants in endothelial cells and hepatocytes(174).  
 
1.2.1.1.3.1 Tumour necrosis factor- 
Macrophages in adipose tissue secrete TNF-(169,175), which is responsible for 
inducing apoptosis of adipocytes and reducing secretion of adiponectin(170,176). 
During obesity, TNF- levels correlate positively with the degree of adiposity(169,176) 
and insulin resistance(177). TNF- may promote the development of insulin resistance 
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and type-2 diabetes through inhibiting insulin receptor signalling and increasing 
secretion of IL-6(177). Neutralisation of TNF- improved insulin sensitivity in rodent 
models(178,179). However, the same effect was not seen in men with metabolic 
syndrome(180), although anti-TNF- blockage improved insulin sensitivity in patients 
with rheumatoid arthritis(181).  
 
1.2.1.1.3.2 Interleukin-6  
IL-6 is a central cytokine secreted by macrophages in adipose tissue(182). IL-6 plays a 
role in the systemic regulation of body weight and lipid metabolism(164,165). Classic 
signalling induces IL-6 to act as an anti-inflammatory cytokine whereas IL-6 can also 
induce pro-inflammatory response via the trans-signalling pathway(164,183,184). 
Increased levels of circulating IL-6 is observed during fat accumulation and a reduction 
in IL-6 is observed with weight loss(185); however, this is not always the case(186). 
There is evidence for trans-signalling from in vitro studies, in which lipid levels and 
mitochondrial activity were reduced in IL-6-treated 3T3-L1 adipocytes, suggesting that 
IL-6 can exert a direct lipolytic effect and induce mitochondrial dysfunction, although 
there was no effect of IL-6 upon insulin responses by treated adipocytes in this 
study(187). IL-6 stimulated lipolysis and fatty acid oxidation in healthy men displaying 
an anti-inflammatory reaction(188). Much of what we understand of IL-6 in the context 
of metabolic inflammation is controversial(164,166,167,188,189); however, we do 
know that IL-6 receptor expression is upregulated in the blood of people with obesity 




1.2.2 Brown adipose tissue 
BAT is a complex tissue composed of adipocytes, stem cells, stromal cells and immune 
cells(190). Compared to white adipocytes, which house a single compartment of fat 
(unilocular), brown adipocytes contain numerous smaller fat droplets (multilocular), 
many more mitochondria(7) and a rich blood supply(143,191,192). BAT plays a vital 
role in metabolic regulation and thermoregulation(8). It is an active hotspot of glucose 
and FFA uptake, and dissipates energy as heat through uncoupled respiration, in which 
expression of uncoupling protein-1 (UCP1) promotes the conversion of FFAs and 
glucose into heat (see Section 1.2.2.2). Thermogenesis processes in BAT regulate 
thermoregulation and glucose homeostasis(193-195). BAT exhibits functional and 
morphological plasticity in response to environmental (e.g. temperature), hormonal (e.g. 
insulin, leptin, corticosteroids) and metabolic challenges (e.g. high fat diet)(190,196). 
 
1.2.2.1 Location and developmental origins of brown adipose tissue 
Originally, BAT deposits were thought to be limited to interscapular regions of rodents 
and the neck region (and mainly supraclavicular but also perirenal areas) of human 
infants and neonates, which atrophied with age(194,197,198). However, with recent 
technological advances (e.g. positron emission tomography, PET scan) BAT has been 
detected in adult humans(144,199,200). New studies suggest that BAT is found in 
several distinct anatomical deposits including subcutaneous (interscapular, subscapular, 
dorsal cervical and axillary regions), intraperitoneal (around kidneys and adrenals) and 
intrathoracic (oesophagus and descending aorta, heat and mediastinal blood vessels) 
sites(196,201) in both humans(200) and rodents(201), with some of these deposits 
depicted in Figure 1.2. The subcutaneous interscapular (i)BAT depot is often 
investigated in rodent studies (Figure 1.2)(201). It has been hypothesized that the 
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location of BAT in the cervical area of humans could regulate the temperature of blood 
supply to the brain and/or modulate vasodilatation(150,202).  
 
Figure 1.2: Typical anatomical sites of brown adipose tissue (BAT) in mice and adult humans. 
In mice classical BAT is found in the interscapular region. Inguinal adipose tissue deposits can 
be composed of brown-in-white (brite tissue), while gonadal adipose tissue are primarily white 
adipose tissue (WAT) in mice. In adult humans, classical BAT deposits are located deep in the 
neck region, proximal to muscle tissue, while brite adipose tissue is located mainly distal to the 
BAT deposits in the neck. In the supraclavicular region in humans, BAT, brite adipose tissue 
and WAT deposits can be found.  
 
 
BAT can be derived through two pathways: the classical (pure) pathway, and through 
conversion of WAT into brite tissue.  Classical or ‘pure’ BAT originates from foetal 
Pax7/Myf5-expressing skeletal muscle progenitor cells to form fully-functional brown 
adipocytes, located in the traditional BAT pads(193,204,205). Recruitable brite 
adipocytes can transiently emerge within traditional WAT deposits, through browning 
agents such as adrenergic stimulation induced by cold stress(146,147,196,206).  
 
1.2.2.2 Physiology and activation of thermogenesis in brown adipose tissue 
Body temperature is maintained when the rate of heat production equals the rate of heat 
loss. Two thermoregulatory heat production mechanisms that compensate for excessive 
heat loss include shivering and non-shivering thermogenesis(201). During shivering 
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thermogenesis, skeletal muscles contract, utilize glucose and produce heat in 
muscle(207). Non-shivering thermogenesis occurs in BAT via uncoupled respiration, in 
which FFAs and glucose are oxidised to produce heat, which may occur in conditions 
below thermoneutrality to maintain body temperature(151).  
 
Thermoneutrality or thermoneutral zone is the temperature range within which the heat 
produced as a byproduct of normal metabolism alone combined with blood flow 
movements allows humans (and mice) to maintain a normal core body temperature of 
approximately 37C(208). Thermoneutral conditions for mice are generally between 30-
32C(208). At a molecular level, thermogenesis in BAT occurs in the mitochondrial 
membrane where UCP-1 (a mitochondrial metabolite transporter) bypasses the 
mitochondrial proton gradient to produce heat, instead of adenosine-5’-triphosphate 
(ATP)(151). The release of norepinephrine from sympathetic nerves, and stimulation of 
- and -adrenergic receptors can also activate thermogenesis in BAT(196,209,210). In 
rodent studies conducted at thermoneutral conditions, UCP-1 ablation was 
obesogenic(59), suggesting that UCP-1 plays a significant role in the development of 
obesity. Below thermoneutrality, UCP-1 protein expression increases in BAT of mice 
fed high fat diet(59,211).  
 
In WAT, recruited brite adipocytes can produce heat via UCP-1-mediated uncoupled 
respiration, potentially as an additional compensatory mechanism induced during cold 
exposure of rodents(206,212,213). Severe adrenergic stress and prolonged elevation of 
norepinephrine levels that may occur during burn injuries induces the emergence of 
brite adipocytes in WAT in humans(197,198). Increased levels of UCP-1 protein was 
observed in beige adipocytes in inguinal WAT upon cold exposure than that observed in 
iBAT suggesting beiging events are more likely to occur in response to cold exposure 
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(214). However, UCP-1 protein is heavily abundant (~250mg) in iBAT compared to 
inguinal WAT (almost 0mg) at temperatures below thermoneutrality (22C)(214). This 
dissipation of energy in the form of heat increases energy expenditure and thus 
activation of thermogenesis in BAT (and brite adipose tissue) could alter the energy 
balance to potentially promote weight loss and improve glucose metabolism(196,215).  
 
1.2.2.3 Effects of cold exposure on the function of brown adipose tissue 
Cold acclimation increases the thermogenic function of BAT, upregulating the 
expression of genes involved in glucose uptake and catabolism including Ucp-1(216). 
In FVB/N mice fed a normal chow, cold exposure (4ºC for 48 hours) increased the basal 
metabolic rate and reduced the signs of type-2 diabetes(216) compared to controls 
(22ºC) or warm acclimated (33ºC, 3 weeks). Similarly, UCP-1 luciferase transgenic 
mice (FVB strain background), had increased expression of UCP-1 protein, tracked via 
measuring bioluminescence in iBAT, following the injection of cold-exposed mice (24 
h exposure at 9 ºC, compared to thermoneutral housing at 28ºC) with the substrate 
luciferin(215).  
 
One problem in understanding the mechanism that controls cold-induced thermogenesis 
is the significant variation (housing, different degrees of cold acclimation, diets, mouse 
strain) in methods employed(217,218). Furthermore, there is substantial variability 
experimentally in the duration of the cold exposure animals are exposed to, which can 
vary from hours to days(219-221). Because of the variability in methodology, there 
have been contradictory reports of the effects of cold exposure on body weight and 
adiposity. In some studies, body weight reductions in rodents exposed to the cold were 
observed, while in others there was no alteration in body weight or fat composition(222-
225). Long-term cold stimulation (4ºC for 1-7 days) of C57Bl/6 mice had only a 
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transient effect on body weight, which returned to initial levels four days after cold 
exposure finished(218). 
 
Rodents are often housed at temperatures (19-25ºC) below thermoneutrality (30-32ºC 
for mice)(208,217) for the comfort of researchers. Low level cold stress induced by 
housing mice at non-thermoneutral temperatures (19-25ºC) may affect the capacity of 
BAT to respond to stimulation. For example, when mice were cold acclimated (4C), 
initially housed at 21C, there was only weak evidence for increased UCP-1 protein 
abundance in classical BAT(214). However, when done at 30C (thermoneutrality) 
large increases in UCP-1 protein were observed in classical BAT(214). This shows us 
that thermoneutrality or the lack thereof can alter the thermogenesis. At temperatures 
below thermoneutrality, classical BAT may expand to browning signals through 
proliferation rather than cellular differentiation(147,214).  
 
BAT activity also increases in humans with cold exposure(210,217,226-230). Four 
months of consecutive blocks of 1-month overnight temperature (ranging from 19C to 
27C) increased the volume of BAT of 5 young healthy men(10,231). Similarly, four 
weeks of cold acclimation (10C for 2 hours daily for four weeks (5 days/week)) 
increased the BAT volume by 45% in 6 healthy lean men(232). Meanwhile, other 
studies have also shown that a small reduction in an ambient temperature (24C to 
19C) was sufficient to increase BAT activity (measured via PET scan) in exposed 
individuals(227). Generally, acute cold exposure (hours) increases BAT 
activity(233,234) while long-term cold exposure (days/weeks) expands BAT 
volume(232,235) in humans.  
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1.2.2.1.1 Seasonal effects on brown adipose tissue 
Seasonal variation in the BAT activity has been observed in several human studies, with 
increased levels of BAT activation (including increased UCP-1) and number of BAT 
deposits observed in the colder winter months(11,233,236-239). Similarly, in winter, 
increases in BAT mass and more brite adipose tissue was observed in Tibetan plateau 
pika (a small mammal)(240). However, not all of these seasonal effects may be 
mediated by temperature, as a study in Dzungarians hamsters showed that exposure to a 
shorter photoperiod (8 hours of light) improved the thermogenic capacity of BAT, 
which may be linked with the capacity of blue light to regulate circadian rhythm(241). 
Indeed, glucose-responsive biorhythms in thermogenesis have been observed in the 
BAT of humans (see also Section 1.3.4)(10). BAT activity could be modified by several 
factors that vary by season (e.g. cold, photoperiod), which may targeted for the 
development of strategies to increase energy expenditure(236).  
 
1.2.2.4 Diet-induced thermogenesis 
Diet-induced thermogenesis (DIT) is the energy expenditure above the basal metabolic 
rate due to the cost of processing food for use and storage(56,242). DIT has been 
suggested to play an important role in the development and management of 
obesity(60,242). Chronic intake of certain diets (high protein) can augment the capacity 
for increased energy expenditure(230). It was hypothesized that in obesity, the high fat 
and carbohydrate diets lead to chronically increased food intake to compensate for low 
protein. This leads to increased leptin secretion, which regulates the activation of BAT 
via the hypothalamus, further elongating the chronic brown fat activation and increasing 
the brown fat recruitment (beige adipocytes, browning). This chronic activation and 
recruitment of BAT has a positive correlation to the degree of obesity(244). This 
hypothesis was confirmed by studies done in Sprague-Dawley rats, in which those fed a  
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cafeteria diet exhibited increased signs of DIT (>100%) compared to rats fed a control 
diet(245). Studies have also shown that when mice (C57Bl/6 background) were exempt 
from thermal stress, UCP-1 ablation prevented DIT, and induced increased weight gain 
(59). DIT was associated with an increased ability of experimental animals fed high fat 
or cafeteria diets to respond to adrenergic stimulation(59,244)(59,245). A diurnal 
rhythm has been observed in the FFA uptake in BAT of wild type C57Bl/6 mice 
whereby FFA uptake was synchronised to photoperiod(246). FFA uptake by BAT 
peaked at the onset of wakening and coincided with the capacity of BAT to clear 
postprandial lipids(246). This study provided further evidence as to why feeding mice at 
‘wrong’ time can be obesogenic(246,247). Activating the DIT pathway or promoting 
BAT activity has great potential as a treatment for metabolic dysfunction resulting from 
energy imbalance(60,248). 
 
1.2.2.5 Brown adipose tissue and obesity 
An inversely proportional relationship has been observed between BMI (and body fat 
percentage) and BAT activity in humans(144,200,234,235,249). Similarly, when brite 
adipocytes were differentiated from abdominal subcutaneous adipose tissue biopsies, 
Ucp-1 mRNA levels were significantly greater in samples from lean individuals 
compared to obese individuals(250). Ucp-1 and -adrenergic gene knockout mice 
gained significant amounts of weight when fed high fat diet housed at 22C(59,209). 
Some hypothesise that diminished BAT activity may be an adaptive trait of obesity, 
given that BAT activity reduces with age, and that increased body fat may provide 
insulation further reducing the need for thermogenesis(193). Alternatively, lowered 
BAT activation could contribute to obesity by reducing whole-body energy expenditure. 
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1.3 Circadian rhythm 
Most living species exhibit a timekeeping system in their body. This biological clock 
allows the organism to prepare for the changes in their physical environment that are 
associated with the light (‘day’) and dark (‘night’) phases to ensure survival. This 
timekeeping allows organisms to adjust their physiology and behavioural outcomes by 
anticipating the daily changes in their environment rather than merely responding to 
these changes in a reactive manner. This process is known as circadian rhythm and 
exhibits self-sustaining cycles of approximately 24 hours, and is entrained by the 24 
hours of light and dark that cycle every day(251). Circadian rhythms in various 
peripheral tissues are controlled by the ‘master clock’, located in the pacemaker cells in 
the suprachiasmatic nerve (SCN) of the hypothalamus (see Section 1.3.1).  
 
The body’s circadian system consists of three major bodies: the oscillatory machinery, 
the input pathway and the output pathway(251). The oscillatory machinery involves the 
SCN and the peripheral oscillators (in peripheral tissues and cells)(252). This temporal 
rhythm is regulated by a transcriptional-translational feedback loop between a set of 
clock genes (see Section 1.3.2)(251). Secondly, the input pathways (or the stimuli that 
regulate temporal rhythm) relay information about the light-dark cycle to the SCN and 
help synchronise the internal homeostasis with the external environment(253)(Figure 
1.3). The output pathways of the intrinsic relationship between the oscillatory 
machinery and the stimuli regulating the machinery are responsible for the coordination 
of the circadian rhythm between the different functions and part of the organism(251). 
This includes neural outputs such as the rhythmic change in the 
parasympathetic/sympathetic balance or the pineal release of melatonin during 
darkness(254,255). These outputs can conversely act as input pathways as well, in a 
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feedback loop regulating most cellular, physiological, metabolic, endocrine and 
behavioural systems in our body(251,256) . 
 
 
Circadian rhythm is governed and/or altered by external stimuli such as blue light, food 
intake, and physical activity(247,251,257,258) (Figure 1.3). A lack of synchronicity 
within between master and peripheral circadian cycles can critically threaten 
survival(259) and/or have long-term adverse consequences for our 
metabolism(6,247,260-262) (see Section 1.3.4). Adipose tissues, like most 
Figure 1.3: An overview of the functional organisation of the circadian system. Inputs from 
the environmental cues such as light, physical activity and food, can reset the phase of the 
central pacemaker so that the period and the phase of circadian rhythm coincides with the 
timing of these external cues. The suprachiasmatic nuclei (SCN), the body’s central 
pacemaker, drives circadian rhythm in other regions of the brain and the body through 
neural and hormonal signals (like melatonin). The SCN receives light-dark cycle information 
through the retinohypothalamic tract via photosensitive retinal ganglion cells containing 
melanopsin. Other peripheral oscillators are usually under the control of the SCN; however, 
during unfavourable circumstances (shift work, jet lag, restricted feeding, sleep disorders) 
these can desynchronise from the SCN. Central pacemakers and peripheral oscillators are 
responsible for the daily temporal cycle observed in most physiological and behavioural 
functions resulting in the regulation of the outputs which can also act as feedback in the 






metabolically active tissues, exhibit a peripheral circadian rhythm(9,10,263). Disruption 
to the rhythmic patterns of gene expression and/or metabolic regulation in these tissues 
could lead to metabolic disorders such as insulin resistance, obesity and type-2 
diabetes(9,263-265). 
 
1.3.1 The master clock 
In mammals, the circadian pacemaker is a bilaterally paired nucleus referred to as the 
SCN(256). The SCN is in the anterior hypothalamus, directly above the optic 
chiasm(256,261,265,266). The SCN is composed of multiple single-cell circadian 
oscillators which when synchronised generate coordinated circadian outputs that 
regulate overt rhythm(266,267). One important feature of SCN is that it encompasses a 
multioscillary system (autonomous) with the entire clockwork residing in single 
neurons which allows all multiple SCN neurons to coordinate with one another to adapt 
the nucleus to different light environments(266-268). SCN cells communicate via a 
vasoactive intestinal peptide (vasopressin), synchronising the body to one 
rhythm(261,269,270). The elastic nature of SCN cells and network explain how most 
physiological and behavioural processes are affected by short or long 
photoperiods(266).  
 
The SCN mediates the body’s ‘photoperiodism’, a process where organisms gradually 
adapt to the length of the daily light period (photoperiod)(271). The SCN receives direct 
input (stimuli) from the eyes in terms of the light (depending on the light and dark 
phases of the day) via the optic chiasm, via the retinohypothalamic tract(256). The SCN 
senses changes in ambient lighting through both direct and indirect retina (via 
photosensitive ganglion cells in the eye containing melanopsin)(272). In this manner, 
light from environment synchronizes the SCN and entrains the 24-hourly circadian 
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rhythms(261,272). Interactions between these ‘clock cells’ in SCN sync individual 
circadian clocks throughout the body (including those in peripheral tissues), to 
coordinate circadian output(272). Ablation of SCN has shown to abolish the circadian 
rhythmicity in the periphery, since the destruction of SCN leads to a loss of synchrony 
amongst individual cells and dampens the rhythm at a population level(273).  
 
The SCN relays information to other hypothalamic nuclei and importantly the pineal 
gland to modulate the production of hormones such as cortisol and melatonin(274) and 
regulates the body’s temperature, and more importantly the circadian rhythm of sleep-
wake cycle(255,264,274). The light and dark cycle of day and night entrains the SCN to 
act every day as a ‘Zeitgeber’ (time-giver, ZT) leading to the 24-hour rhythmicity(275). 
Peripheral tissues can have independent circadian clock rhythms, which are 
synchronised by the SCN(276). Interaction between the peripheral tissue clocks and 
SCN ensures synchronisation of important processes throughout the body(277). Genes 
such as Bmal1, Per, Cry, and Clock amongst many others (more than 14) form a core-
clock regulatory network and help establish this oscillation and synchronisation 
between the SCN and peripheral local clocks(278) (see Section 1.3.2). Studies have 
pointed towards the existence of nervous pathways that link the SCN with various 
tissues such as heart, liver, pancreas, and pineal gland(9,254,255). The SCN can thus 
activate or silence different tissues and their functionality depending on the stimuli 
received and the time of the day(251). Disruption in circadian rhythm or a 
desynchronization of peripheral clocks with the SCN can have detrimental effects on 
metabolism(256,279,280).   
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1.3.2 The molecular circadian clock mechanism 
Almost all metabolically active tissues display a rhythmic oscillation, which are 
controlled by the master clock(280). On a molecular level, the circadian clock is 
regulated through a negative and positive feedback network called the transcription 
translation oscillation loop(281). The temporal proteins CLOCK and BMAL1 
heterodimerize and interact with the E-box response elements in the promoters of the 
target genes which drive the positive transcription arm of the transcription translation 
oscillation loop. These positive target genes include Period (Per1, Per2, Per3) and 
Cryptochrome (Cry1, Cry 2). Once translated, Per and Cry proteins interact, translocate 
into the nucleus and inhibit the activity of CLOCK and BMAL1, which promotes the 
repression arm of the transcription translation oscillation loop by repressing (REV-
ERB) of Bmal1 gene expression(282). All clock genes have been shown to have a 
~24-hour rhythmic expression(268,278). Moreover, modulated by melatonin the core 
oscillator system is connected with various tissue-specific proteins (e.g. PPAR) that 
undergo circadian cycling and feed into the SCN(251), which connect oscillators with 
metabolic sensing and mitochondrial function(285,286). As metabolic sensors these 
oscillator components are highly relevant to health and metabolic disorders such as 
type-2 diabetes(251,287), since they can modulate the synchronisation between the 
central and peripheral oscillators.  
 
1.3.3 Chronodisruption  
The cycle of sunrise and sunset has provided a reliable time cue for many thousands of 
years, until recently where modern life and the intensified exposure of humans to 
artificial lighting environment, day and night. Our altered lifestyle from our ancestors 
has led to a lifestyle shift where we now longer are only exposed to the naturally-
occurring light and dark cycles of day and night (288). While central-to-peripheral 
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synchronisation allows a means for organs and tissues to function with maximum 
efficiency, it is suggested that desynchronization of this timing due to various disruptors 
can contribute to the development of diseases (289). An altered or desynchronised 
circadian rhythm is referred to as chronodisruption(5,290). Chronodisruption has been 
linked with an increased risk in developing obesity and metabolic dysfunction(263,291). 
Chronodisruptors are external or internal exposures or effectors which are 
chronobiologically active and can thus disrupt the timing and order of circadian rhythm 
in the body(291).  
 
1.3.3.1 Factors contributing to chronodisruption  
The input pathways, which govern the master circadian rhythm, can also induce 
chronodisruption, should the stimuli be presented out of the ‘normal’ anticipated 
timeframe(251,264,279). Thus, external factors such as blue light, food intake and 
physical activity received at the wrong time (e.g. during shift work, or changing time 
zones) cause chronodisruption (247,259,262,279,290,292-297). Moreover, 
physiological conditions such as sleep disorders and aging can also disrupt normal 
circadian rhythm(251,262). 
 
1.3.1.1.1 Light at night 
Blue light (460-480 nm) at night can disrupt circadian rhythm and suppress the 
production of melatonin(298). This hormone plays an important role in day-to-day 
physiology(274,279,299,300). Circulating levels of melatonin are inversely proportional 
to light intensity and length of exposure(295). Melatonin is a hormone produced in the 
pineal gland in mammals(274,301). It exhibits a circadian rhythm and is actively 
involved in the entrainment of the body’s circadian rhythms, including sleep-wake 
cycles, seasonal reproduction and blood pressure regulation(111). Melatonin production 
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in infants become regular after three months of age, with the highest concentrations 
measured in blood between midnight and 8 am(260). Epidemiological studies in 
humans and experimental studies in animals have documented the negative 
consequence of chronodisruption and nocturnal melatonin inhibition: ranging from 
altered sleep cycles to increased cancer risk(298,302). The introduction of artificial light 
and work at night time has now been identified as a major physiological challenge 
causing metabolic dysfunction by increasing hunger, modifying satiety hormone 
signalling, and impairing glucose and lipid metabolism(288).  
 
1.3.1.1.2 Shift work 
Shift work disturbs the ‘natural’ daily light/dark cycle in shift workers(251). Night shift 
workers suffer from a disturbance in the natural daily light/dark cycle and have 
impaired melatonin rhythm(292,303-305). Moreover, shift workers are at increased risk 
of metabolic dysfunction such as obesity(292). Shift work alters the normal circadian 
rhythm where the peak active photoperiod switches from light to dark, which also 
means a change in the normal feeding pattern from light to dark(292). Similarly, mice 
fed in the light phase exhibit increased adiposity compared to mice fed in the dark phase 
(normal for mice)(247,299,306).  
 
1.3.3.4 Chronodisruption and its effects on metabolic function 
Changes in circadian rhythm impact the metabolic homeostasis and the expression of 
clock genes(288).. Evidence from both in vitro and human studies have suggested that 
expression of the circadian clock transcription network in the adipose tissue can 
influence both adipogenesis and the lipid distribution(312,313). Diet-induced obesity 
altered the circadian behaviour and molecular rhythms in C57Bl/6 mice, attenuating the 
magnitude of diurnal rhythm of feeding and locomotor activity, with mice fed a high fat 
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diet increasing their food intake during the inactive period (light phase)(263). 
Interestingly, genetically obese animals were resistant to weight gain when feeding was 
restricted to the active (dark) phase(307). Studies have also suggested that disruption of 
the circadian rhythm by chronodisruptors in the SCN and the peripheral tissues may 
lead to development of metabolic syndrome(9,288,308). Melatonin absence (in case of 
shift work and light at night) has been known to lead to long term resistance from leptin 
(309). Leptin alteration due to chronodisruption can also lead to metabolic 
dysfunction(155,309).   
 
Thus, it is critical to understand the circadian control of glucose metabolism. Human 
studies have demonstrated rhythmic variations in glucose tolerance and insulin action 
throughout the day(314,315). Additionally, oral glucose tolerance is impaired in the 
evening compared to the morning which may be attributed to a combination of both 
reduced insulin secretion and altered insulin sensitivity in the evening(314,316). The 
‘dawn phenomenon’ is a well-known described phenomenon where glucose levels are 
known to peak before the onset of active period(317,318). Disruption in the normal 
cyclic pattern of glucose tolerance is a hallmark of type-2 diabetes(288),  
 
Numerous genes including nuclear receptor expression controllers have a circadian 
pattern of expression in BAT(9,310,311). Lee et al (2016) in a series of in vitro and in 
vivo experiments captured the circadian rhythm of glucose-responsive BAT activity in 
humans(10). They also found the level of BAT abundance was associated with 
glycaemic fluctuations. Low BAT density was associated with greater glycaemic 
fluctuations throughout the day(10). Both inter- and intraorgan desynchrony may be 
involved in the pathogenesis of metabolic dysfunction attributable to effects of brain, 
and multiple metabolic tissues such as muscles, liver, adipose tissue and gut(288). Thus, 
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strategies to improve synchrony between the cycles of sleep/wakefulness and 
feeding/fasting may aid the physiological processes including lipid metabolism, satiety 
and inflammation.  
 
1.4 Sun exposure 
1.4.1 Ultraviolet radiation 
UVR, derived from sunlight, is categorized into ultraviolet A (UVA, 315-400nm), 
ultraviolet B (UVB, 280-315nm) and ultraviolet C (UVC, 100-280nm) radiation(319). 
UVC radiation does not reach the surface of earth, as it is completely absorbed by the 
earth’s ozone layer. Most of UVB radiation is also absorbed by the ozone layer such 
that terrestrial UVR is composed mainly of UVA (90-95%) and some UVB (5-10%) 
radiation. UVR levels in sunlight depend on geographical location, altitude, time of day 
and season.  
 
1.4.2 Ultraviolet radiation and skin  
UVA radiation penetrates though dermal compartments of skin while UVB radiation 
can reach the upper layers of dermis(320). Melanin content in skin is a major 
determinant of skin colour and UVR sensitivity(321). Melanin is composed of a number 
of different pigment subunits and is available in a couple of different chemical forms in 
the body(322). Eumelanin is a darker pigment that is readily expressed in heavily 
pigmented individuals while pheomelanin is a lighter-coloured sulphated pigment. 
Eumelanin is significantly more effective in blocking UV photons compared to 
pheomelanin, hence the greater the eumelanin content the less UVR is able to penetrate 
through skin(321,322).   
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1.4.3 Risks associated with excessive exposure to ultraviolet radiation  
Melanoma rates in Australia are amongst the highest in the world, and are caused by 
DNA damage from sun exposure(323). In 2015, melanomas costed the New South 
Wales (Australian state) healthcare system AUD536 million(324). There are well- 
established links between excessive exposure to UVR found in sunlight and the 
initiation and development of both non-melanoma (keratinocyte) and melanoma skin 
cancers(325). DNA-damaging molecules (hydroxyl and oxygen radicals) are generated 
in skin following exposure to UVA radiation, and can indirectly cause skin cancer(326). 
Excessive UVB radiation causes sunburn and is directly absorbed by and damages DNA 
(inducing thymidine dimers) and promoting the initiation of skin cancer 
development(326,327). UVB radiation is known to be more DNA-damaging than UVA 
radiation when comparing the same dose(328,329). Exposure to either UVA or UVB 
radiation damages collagen fibres, and accelerates skin aging(326). Excessive exposure 
to UVR is also linked to ocular diseases such as cataracts and 
photokeratoconjunctivitis(330).  
 
1.4.4 Potential benefits of ultraviolet radiation  
Sun exposure plays an important role in maintaining vitamin D levels, which are 
important for bone health(331-335). Sun exposure in early life may also prevent the 
development of autoimmune and allergic diseases, including rheumatoid arthritis, lupus 
erythematosus and allergic asthma(336,337). Exposure to UVR is also hypothesized to 
prevent the development of some childhood cancers such as acute lymphoblastic 
leukaemia and hepatoblastoma(338). Exposure to UVR produces an inflammatory 




A good example of the protective effects for sun exposure in limiting the development 
of autoimmune disease is observed for multiple sclerosis, a chronic inflammatory 
disease characterised by demyelination of nerves in the central nervous system(340).  
The aetiology of multiple sclerosis involves both genetic and environmental factors, 
with sun exposure exerting effects potential through vitamin D-dependent(294) and 
independent-pathways(341). Below we describe how exposure to UVR and its induced 
mediators, vitamin D and nitric oxide may reduce the development of obesity and type-
2 diabetes.  
 
1.4.4.1 UVR-induced vitamin D 
Vitamin D deficiency is a major global public health issue(320,333,342-344). Vitamin 
D deficiency is clinically defined as a serum concentration of 25-hydroxyvitamin D 
(25(OH)D) of less than 50 nmol/L(332). Vitamin D is fat-soluble and plays a crucial 
role in bone mineralisation and other related processes that govern skeletal growth and 
calcium and phosphate homeostasis(320,344). Vitamin D can be obtained from dietary 
sources as cholecalciferol (vitamin D3, animal-based; e.g. oily fish, eggs) and 
ergocalciferol (vitamin D2, plant-based; e.g. mushrooms)(320,333,335,344,345). 
Dietary sources only account for about 5-10% of an individual’s circulating 
25(OH)D(325), with most vitamin D obtained through skin exposure to UVB 
radiation(346). The precursor molecule 7-dehydrocholestrol is converted to pre-vitamin 
D3 following exposure to UVB radiation. This pre-vitamin D3 is then quickly 
transformed structurally by thermal induction to form vitamin D3(347). Vitamin D3 is 
then transported into the blood stream to the liver. Circulating vitamin D metabolites are 
primarily bound to vitamin D binding protein with a smaller fraction bound to albumin 
or circulate free in the blood stream. In the liver, vitamin D undergoes hydroxylation to 
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form 25(OH)D. Levels of the metabolite 25(OH)D, that are used to determine an 
individual’s vitamin D status(320).  
 
Up to one billion people worldwide are estimated to be vitamin D deficient(348), which 
may be caused by the increasingly indoors lifestyles of modern human populations, and 
health concerns of excessive sun exposure. Vitamin D deficiency has been observed in 
individuals residing in low latitude nations (i.e. living close to the equator), where 
terrestrial UVR levels should be adequate to maintain normal 25(OH)D levels(344). 
This may be due to our increased indoors lifestyle and clothing obstructing the UVB 
exposure from sunlight(333). Understandably, seasonal variations have been observed 
in the vitamin D status of individuals. Rates of vitamin D deficiency were much lower 
in summer (14%) compared to winter (36%)(349). There may be significant regional 
and demographic variation, with vitamin D deficiency more prevalent in certain 
demographic such as the elderly and people with darker skin pigmentation(350). 
Another factor that modulates vitamin D status is obesity(350). It is generally thought 
that obese individuals may be at a higher risk of vitamin D deficiency due to the fat-
soluble properties of vitamin D. Vitamin D deficiency could increase the risk of 
developing chronic metabolic diseases such as obesity, type-2 diabetes and 
CVD(342,343,350,351). However, there may be reverse causality, in that reduced 
serum 25(OH)D levels in obese and overweight individuals may result from reduced 
sun-seeking behaviours(331,334). It is unclear at this stage whether vitamin D 
deficiency is a cause or an effect of increased adiposity and metabolic dysfunction(334).  
 
1.4.4.2 UVR-induced nitric oxide 
Skin exposure to UVR releases photolabile nitric oxide species such as nitrite and 
nitrosothiols into the circulation from precursors stored in the dermis(352,353). Whole 
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body exposure to UVA radiation increased the bioavailability of nitric oxide, increased 
circulating levels of nitrite and reduced mean arterial pressure and diastolic blood 
pressure of young healthy male volunteers(354). The vasodilating effect of nitric oxide 
was independent of nitric oxide produced through inducible nitric oxide synthase 
(iNOS)(354). In studies performed in our laboratory, exposure to UVR or topical 
treatment with nitric oxide donor, S-nitroso-N-acetylpenicillamine (SNAP), increased 
nitric oxide concentrations in the skin of C57B1/6J mice(1). Similarly, topical treatment 
of skin of C57Bl/6J male mice following UVR exposure with 2-(4-carboxyphenyl)-
4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide potassium salt (cPTIO), a nitric oxide 
scavenger, reduced the skin levels of nitric oxide increased by UVR(1).  
 
1.4.4.2.1 Physiology of nitric oxide  
Nitric oxide has various actions and targets, which can have short- and/or long-term 
effects on cell regulation and function(355). Nitric oxide is produced through NOS 
enzymes, which catalyse the nicotinamide adenine dinucleotide phosphate and oxidise 
L-arginine to L-citrulline producing nitric oxide(355). Nitric oxide can be produced by 
three isoforms of NOS: neuronal NOS (nNOX/NOS1), inducible NOS (iNOS/NOS2) or 
endothelial NOS (eNOS/NOS3)(356). Nitric oxide can also arise from nitrate-nitrite-
nitric oxide pathway, which is thought to be an important alternative pathway for nitric 
oxide production(357). Nitrate enters the cell membrane and is reduced to form nitrite 
and then nitric oxide. Nitric oxide is best known as a regulator of blood flow(355), and 
emerging findings suggest that it has protective roles in regulating metabolic function. 
Nitrate can increase the expression of UCP-1 to induce WAT browning(357) (see also 
Section 1.4.5.3 below). Nitric oxide may also regulate neurotransmission, learning, 
memory, gene transcription, platelet aggregation, immunity and angiogenesis(355).  
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1.4.4.2.2 Regulation of cardiometabolic dysfunction by nitric oxide 
Studies conducted in both animals and human models of obesity have shown that there 
is reduced bioavailability of nitric oxide(358-360). Since the availability of nitric oxide 
is dependent on the balance between generation and degradation of nitric oxide, the 
reduced nitric oxide may be the result of decreased expression of NOS, impairments in 
NOS activity and/or the increased reaction of nitric oxide with reactive oxygen species 
(ROS)(355). Nitric oxide, being an important signalling messenger, is involved in the 
regulation of food intake in a number of species including rodents(361-363). Dietary 
nitric oxide supplementation may limit weight gain and promote insulin sensitivity in 
humans(364-367). Similar effect was also seen in C57B1/6 mice fed an isocaloric 
diet(368,369). eNOS knockout mice reduced the capacity to produce nitric oxide and 
exhibited an increase in WAT accumulation, hepatic steatosis and insulin resistance 
compared to the wild-type(370,371). Furthermore, iNOS/nNOS/eNOS triple knockout 
mice exhibited an increase in visceral obesity, hypertension and impaired glucose 
tolerance compared to the wild-type mice(372). Zucker rats administered L-arginine via 
drinking water had enhanced nitric oxide(x) (oxidation products of nitric oxide), 
increased the BAT mass and displayed an improvement in their metabolic profiles when 
obesity was induced genetically or through the diet(373,374). In humans, genetic 
polymorphisms of NOS isoforms have also been linked to insulin resistance(355). 
Premenopausal women with central obesity treated with L-arginine (5 g/day) had 
reduced waist circumference after 6 weeks(375). More so, improved vascular 
endothelial insulin uptake was observed by administering nitric oxide donors in rat 
skeletal muscles(355,376). Further research is required to investigate the specific 
mechanism of action of nitric oxide and how may regulate the development of obesity 
and type-2 diabetes.  
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1.4.5 Effects of exposure to UVR or sunlight on metabolic dysfunction 
 
1.4.5.1 Human studies  
There may be beneficial effects of exposure to UVR from sunlight in preventing or 
reducing metabolic dysfunction(12,351).  
1.4.5.1.1 Seasonal variation 
Human epidemiological studies have observed an increase in BMI, abdominal obesity 
and HbA1c levels during winter(377,378). Higher rates of type-2 diabetes were 
observed during winter in children (6-11 years of age)(379,380). In contrast, an increase 
in weight gain was observed in Texan adolescents during the summer holidays 
compared to the school year, which might be due increased time spent sedentary and 
indoors during summer(381). Women who had pregnancies conceived during winter 
were at an increased risk of developing gestational diabetes mellitus compared to 
pregnancies conceived in summer(382).  
 
1.4.5.1.2 Sun-seeking behaviours 
In a study of 24,000 Swedish women, those who participated in sun-seeking behaviours 
had a 30% reduced risk of developing type-2 diabetes(383), experienced fewer 
thromboembolic events and reduced all-cause mortality(383-385). Adults participants 
from Saudi Arabia asked to engage in more sun-seeking behaviour and eat vitamin D-
rich foods had a reduced risk of metabolic syndrome compared to control 
participants(386). However, in another study, there was no significant relationship 
between increased daily sun exposure and BMI, body fat proportions, and fasting blood 
sugar levels in adult men from India, although blood LDL-cholesterol levels were 
reduced in men with increased sun exposure(387). Differences in ethnicity and skin 
melanin content could account for inconsistencies between these findings. 
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1.4.5.2 Experimental animal studies 
Experimental animal studies published by our laboratory have established that ongoing 
exposure to low dose (1 kJ/m2) UVR reduced weight gain and the development of 
glucose intolerance, insulin resistance and liver steatosis in C57B1/6 mice fed a high fat 
diet(1). The effects of UVR in this study were independent of vitamin D 
supplementation, with dietary vitamin D supplementation having only a limited effect 
on hepatic steatosis and no other measures of metabolic syndrome(1). In another study 
performed with Lewis rats with diet-induced NAFLD, ongoing UVR exposure 
improved reduced hepatocyte apoptosis, inflammation, and the degree of insulin and 
leptin resistance compared to control rats(388).  
 
UVR-induced release of nitric oxide may modulate weight gain and the development of 
signs of metabolic syndrome in mice fed a high fat diet(1,102). Skin exposure to UVR 
or a nitric oxide donor (SNAP) reduced body weight and the severity of insulin 
resistance induced by feeding the mice a high fat diet, while cPTIO reversed the 
suppressive effects of UVR on fasting glucose and liver steatosis(1). Similar beneficial 
effects of UVR-induced nitric oxide were observed in UCP-1 luciferase male mice 
(FVB/NJ background) fed a high fat diet, with low dose UVR reducing the extent of 
NAFLD and glucose intolerance in a nitric oxide-dependent fashion(389). Low dose 
UVR was less effective at suppressing weight gain in UCP-1 luciferase transgenic male 
mice fed a high fat diet, which may be explained by the increased resistance of the 
strain background (FVB/NJ) of this transgenic mouse to the obesogenic effects of eating 
a high fat diet(79), and/or the capacity of low dose UVR to affect adiposity in mice of 
this genetic background. Overall, findings from animal studies suggest a protective 
effect of ongoing exposure to low dose UVR upon the development of metabolic 
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dysfunction and obesity, through release of nitric oxide from dermal stores(1,102,389), 
with further studies needed to identify the mechanism(s) underlying these observations. 
 
1.4.5.3 Nitric oxide and brown adipose tissue 
A number of studies have aimed to investigate, identify and quantify the role of nitric 
oxide in activating thermogenesis in BAT(1,389,390). During activation of BAT there 
is an increased blow flow to this tissue and it has been theorized that nitric oxide release 
from the systemic nervous system could enhance thermogenesis in BAT(391). Indeed, 
nitric oxide was observed to enhance the thermogenic function of BAT during cold-
acclimation of immobilized stress adaptive rats(390). Similarly, nitric oxide may 
mediate the noradrenaline-induced BAT thermogenesis to enhance non-shivering 
thermogenesis during cold-acclimation(392). This observation may have been 
facilitated by the expression of NOS enzymes, particularly eNOS(390,393) Nitric oxide 
may regulate metabolism and promote mitochondrial biogenesis in BAT via the nitric 
oxide-cGMP-dependent pathway(371). 
 
In our laboratory, a recent study in UCP-1 transgenic male mice was carried out to 
assess the role of nitric oxide released from UVR-exposed skin in modulating the UCP-
1 expression in iBAT; however, no significant effects were observed(389).. A major 
reason for the limited effect of UVR on UCP-1 expression in UCP-1 luciferase 
transgenic mice, may have been due to the measurement of UCP-1 expression at only 
one timepoint across a 4 hour period in the middle of day, when done during the 12-
week experiment. More recent studies suggest that UCP-1 expression has a circadian 
rhythm in iBAT(246), and therefore the effects of any mediators on its expression need 
be examined throughout the day, with consideration of their potential to modulate 
circadian rhythm. Therefore, our previous studies(389) may not have detected 
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differences induced by UVR exposure, as they were not designed to measure its 
potential to modulate UCP-1 expression throughout the day, and the circadian rhythm 
of UCP-1 expression.. Thus, the focus of the current study was to investigate the effects 
of the effects of nitric oxide released by UVR exposure on the circadian rhythm of 
UCP-1 expression in iBAT of UCP-1 transgenic mice fed a high fat diet.   
 
1.5 Summary 
Metabolic dysfunction and obesity prevalence is steadily increasing in Australia and 
worldwide(31). The relationship between obesity and the increased risk of developing 
co-morbidities such as type-2 diabetes, NAFLD, CVD and dyslipidaemia is well 
established(2). The Australian and worldwide healthcare systems are greatly burdened 
by the financial and health costs of obesity and metabolic dysfunction. Current 
treatments for obesity and type-2 diabetes are ineffective in long-term or not feasible for 
the wider population. There is an urgent need for the development of novel and 
effective treatments. Some clinical and epidemiological studies have suggested that sun 
exposure may also be beneficial to improve metabolic function in 
humans(325,334,341,345,383,386,394). Our animal modelling studies have suggested 
that chronic low dose exposure to UVR prevents weight gain and suppresses signs of 
type-2 diabetes in mice fed a high fat diet, through nitric oxide-dependent 
mechanisms(1). We hypothesised that UVR-induced nitric oxide may exert protective 
effects through activating thermogenesis in BAT. In our previous study, ongoing 
exposure to low dose UVR did not modulate the expression of UCP-1 the iBAT of 
UCP-1 luciferase transgenic mice fed a high fat diet (389). However, more detailed time 
course measurements are necessary than those previously undertaken, as recent findings 
have identified that UCP-1 expression has a circadian rhythm in BAT. In the current 
study, we hypothesised that low dose UVR may alter the circadian rhythm of UCP-1 
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expression (thermogenesis) in the BAT of mice fed a high fat diet. Furthermore, we also 
wanted to determine whether any alterations in the biorhythm of UCP-1 expression and 
any protective effects on metabolic dysfunction were mediated by nitric oxide.  
 
1.6 Hypothesis and aims 
 
1.6.1 Hypothesis 
We hypothesized that the ongoing exposure of mice fed a high fat diet to low UVR will 




Aim 1: To examine the effects of low dose UVR on the circadian rhythm of 
thermogenesis (UCP-1 expression) in iBAT and glucose levels in blood of UCP-1 
transgenic mice fed a high fat diet. 
Aim 2: To determine if any observed effects of UVR on the circadian rhythm of 
thermogenesis and blood glucose, and metabolic dysfunction, are dependent on the skin 





Chapter 2: Methods 




The experiment described below was approved by the Telethon Kids Institute Animal 
Ethics Committee (AEC#315). All individuals involved in the handling of animals 
during the study were certified under Telethon Kids Institute policies and received 
appropriate ongoing training from the Animal Welfare Officer (Dr Emily Barrick). All 
procedures performed on animals involved in this project were done in accordance with 
Standard Operating Procedures (#01, 10, 18, 26, 28, 29, 36, 40 and 50) of the Telethon 
Kids Institute and conformed to the Australian Code for the Care and Use of Animals 
for Scientific Purposes of the National Health and Medical Research Council of 
Australia. 
 
2.2 Experimental animals 
UCP-1 luciferase transgenic male mice (‘thermomouse’ strain; on an FVB/NJ 
background strain) were obtained from the Jackson Laboratory (USA) in November 
2015. Mice were housed and bred at the Bioresources Centre at the Telethon Kids 
Institute (Subiaco, Australia). Mice were housed individually, under controlled living 
conditions in open top cages. Controlled housing parameters included ambient room 
temperature (22.2  0.1, mean  SEM) and lighting (12 hours light/dark cycle). The 
room temperature was recorded daily throughout the experiment from an average of 3 
wall thermometers placed around the animal housing room. Perspex-filtered fluorescent 
lights in the animal facility did not emit any detectable UVR (as measured using an 
ultraviolet radiometer (UVX Digital Radiometer, Ultraviolet Products Inc., Upland, 
USA). All mice had access to their relevant diet and water ad libitum, apart from during 
specific fasting assays, described below.  
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2.2.1 UCP-1 luciferase transgenic mouse 
Galmozzi et al. (2014) originally generated the UCP-1 luciferase transgenic mice used 
in this study(215). The Ucp-1 gene locus and a luciferase2-T2A-tdTomato reporter 
cassette, was inserted at the initiation codon for the Ucp-1-coding sequence located in 
exon 1 using BAC recombinant engineering techniques(215). The Ucp-1 luciferase 
BAC DNA was microinjected in single cell FVB/NJ embryos and transgenic founders 
and their offspring identified by PCR(215). Segregation patterns conducted on the 
generated mice indicated that the transgene was inserted into the Y chromosome(215). 
Thus, male UCP-1-luciferase transgenic mice were purposely chosen for this study, as 
bioluminescence detection of activation of the Ucp-1 promoter, following injection of 
the chemical D-luciferin, is limited to BAT of male mice(215).  
 
2.3 Experimental protocol 
From 4 weeks of age, male UCP-1 transgenic mice were fed a low fat, vitamin D-
deficient diet until adulthood (8 weeks of age) (Figure 2.1). This was done as vitamin D 
supplementation through the diet prevents the beneficial metabolic effects of low dose 
UVR(1). At 7 weeks of age, 80 mice were randomly allocated into four treatment 
groups (n=20/treatment. See Figure 2.1), that were separated into two batches for 
logical purposes around animal management requirements for the circadian 
measurement (over 28 hours) of UCP-1 expression in iBAT, and weekend access to 
equipment (particularly the IVIS Bioimager). There was a one-week difference in the 
starting and finishing times of batch 1 and batch 2 of the experiment, with all data 
combined within treatments. There were no differences in the starting weights of mice 




Mice were exposed to 1 of these 4 treatments, as per below: 
1. Fed a low fat diet, and mock-irradiated twice a week (negative control, n=20); 
2. Fed a high fat diet, and mock-irradiated twice a week (positive control, n=20); 
3. Fed a high fat diet, and exposed to low dose UVR (1kJ/m2) twice a week (n=20); 
or, 
4. Fed a high fat diet and exposed to low dose UVR (1kJ/m2) and topically treated 
with the nitric oxide scavenger, cPTIO (0.1 mmol), twice a week (n=20).  
 
 
Figure 2.1: Experimental protocol and timeline. Four-week-old male UCP-1 transgenic mice 
were fed a low fat diet (LFD) for 4 weeks, until 8 weeks of age. Mice were separated into four 
treatments (n=20 mice/treatment), in which mice were: 1. Fed a LFD and mock-irradiated 
twice a week (LFD; 2. Fed high fat diet and mock-irradiated twice a week (HFD); 3. Fed a high 
fat diet with 1kJ/m2 UVR administered twice a week (HFD + UVR); or, 4. Fed a high fat diet 
with 1kJ/m2 UVR administered followed by topical cPTIO (0.1 mmol) twice a week (HFD + UVR 
+ cPTIO). The circadian rhythm of UCP-1 expression in iBAT, glucose in blood and body 
temperature were measured over 28 h at three time points; baseline (at 8 weeks of age), and 




2.4 Experimental diets 
All experimental mice were fed a low fat diet, non-vitamin D-supplemented diet (SF12-
029; Speciality Feeds, Glenn Forrest, Western Australia, Table 2.1) from four until 
eight weeks of age. Then, mice in treatments 3 and 4 were exposed to 1 kJ/m2 UVR, 
with mice in treatments 1 and 2 ‘mock-irradiated’ as described below (Section 2.6). 
Immediately after these treatments, mice in treatments 2-4 (Figure 2.1) had their food 
changed to a high fat diet (Table 2.1) (23% lard with canola oil, SF12-031, Speciality 
Feed, Glen Forrest, Australia). These diets have been used previously to induce 
significant weight gain and/or signs of type-2 diabetes in C57Bl/6J and UCP-1 
luciferase transgenic mice(1,389). Diets were supplemented with calcium (2%) but not 
with vitamin D to observe the full effect of ongoing exposure to UVR on weight gain 







Ingredients (g/10g) High fat diet  
(SF12-031)* 
Low fat diet  
(SF12-029)* 
Casein acid 2.00 2.00 
Sucrose 1.00 1.00 
Canola oil 0.290 0.50 
Lard 2.070 - 
Cellulose 0.500 0.500 
Wheat starch 1.740 3.600 
Dextrinised starch 1.320 1.320 
DL Methionine 0.030 0.030 
Calcium carbonate 0.252 0.252 
Sodium chloride 0.026 0.026 
AIN93 trace minerals 0.014 0.014 
Potassium citrate 0.015 0.015 
Dicalcium phosphate 0.510 0.510 
Potassium dihydrogen phosphate 0.076 0.025 
Choline chloride (75%) 0.025 0.025 
Magnesium oxide 0.017 0.017 
Modified AIN93 vitamins (no vitamin D 
added) 
0.100 0.100 
Digestible energy (MJ/kg) 18.4 15 
*Table 2.1 is adapted from information supplied by Speciality Feeds, the provider of these experimental 
diets. This table contains the formulation of both the high fat diet and the low fat diet, which are semi-
purified diets. These diets were not supplemented with vitamin D, to ensure that the effects of UV 
exposure were not masked by dietary vitamin D supplementation(1). 
 
 
2.5 Removing hair from dorsal skin 
At the 8 weeks of age, a 2cm by 4cm patch of fur was shaved from dorsal skin using a 
rotary motor clipper (WAHL, KM-2) (Figure 2.2). Dorsal fur was removed 
throughout the experiment, every 2-3 weeks as needed.  
 
Table 2.1: Nutritional composition of rodent diets. 
 




Figure 2.2: Shaved dorsal skin and administration of ultraviolet radiation. Adult male UCP-1 
transgenic mice, with shaved dorsal skin surfaces, housed in individual compartments of a 
Perspex box, with wire mesh and PVC sheet placed on top to cover the box. Mice were 
exposed to 1kJ/m2 UVB radiation from the sunlamps. 
 
 
2.6 Exposing mice to ultraviolet radiation 
From eight weeks of age, mice in treatments 3 and 4 were exposed to low dose UVB 
radiation (1kJ/m2), twice a week. This was usually done on Monday and Thursday 
mornings between 9 and 11 am, except for the baseline, week 6 and week 12 time-
points (circadian analyses, Table 2.2), when UVR was administered first on a Saturday, 
and then the following Tuesday. This 1 kJ/m2 dose of UVB radiation was a sub-
oedemal (non-burning) dose for mice on the FVB/NJ background as determined 
previously using the FS40 sunlamps to administer UVB radiation(389). Mice in 
treatments 1 and 2 were mock-irradiated and underwent the same handling and housing 
procedures as mice in treatments 3 and 4, except that they were ‘exposed’ to fluorescent 
lighting instead of UVR. Prior to each UVR treatment, UVB output was measured using 
a UVB radiometer (UVX Digital Radiometer, Ultraviolet Products Inc., Upland, 
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California, USA). The following formula was used to calculate the time mice spent 
under the lamps to obtain a 1 kJ/m2 dose of UVB radiation: 
𝐸𝑥𝑝𝑜𝑠𝑢𝑟𝑒 𝑑𝑢𝑟𝑎𝑡𝑖𝑜𝑛 (𝑚𝑖𝑛𝑠) =
1000 ∗ 𝑈𝑉 𝑑𝑜𝑠𝑒 1
𝑘𝐽
𝑚






For both mock and UVR treatments, mice were placed into a Perspex box, within 
individual compartments, with a wire mesh was placed over the top (Figure 2.2). A 
polyvinyl chloride (PVC) plastic sheet was placed over the wire mesh to block UVC 
radiation emitted from sunlamps. UVR was administered from a bank of six FS40 
lamps (Phillips, TL 40W/12 RS, New South Wales, Australia). Mice receiving the mock 
irradiation (treatments 1 and 2, Figure 2.1) were placed into the individual 
compartments in a Perspex box, with a wire mesh, and the PVC sheet on top (Figure 
2.2) for the same time as mice exposed to UVR under fluorescent lighting.  
 
2.7 Topical skin treatments with nitric oxide scavenger 
A vehicle of ethanol, propylene glycol, and double distilled water (2:1:1) was 
administered to mice in treatments 1, 2 and 3 (Figure 2.1). This vehicle was also used 
for the application of cPTIO (2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-
oxyl-3-oxide potassium salt) (0.1mmol in 100L; Sigma-Aldrich) to mice in treatment 
4.  Using a pipette, cPTIO (which is sensitive to bright light) was topically applied to 
shaved dorsal skin immediately after exposure to UVR in a darkroom (with red light for 
visibility). The dorsal skin of mice in treatments 1-3 was treated with 100µl of vehicle 
immediately following mock-irradiation or exposure to UVR.   
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2.8 Circadian analyses 
Interscapular skin temperature, blood glucose and UCP-1 expression in iBAT were 
measured every 4-6 hours over a 28-hour window at three time points (baseline, week 6 
and week 12; Figure 2.1). At baseline, week 6 and week 12, interscapular skin 
temperature (n=20/treatment), blood glucose (n=20/treatment) and UCP-1 
bioluminescence (n=12/treatment) were measured at the time described in Table 2.2. At 
the baseline time point (week 0), at ZT3 (9 am), mice were treated with low dose UVR 
(1kJ/m2) and then topically with vehicle (Treatment 3) or cPTIO (0.1 mmol, treatment 
4), or mock-irradiated (treatments 1 and 2) (Figures 2.1). The low fat diet for mice in 
treatments 2-4 (Figure 2.1) were replaced with high fat diet immediately after this first 
treatment of mice with mock- or UVR-radiation. This was the first time mice in 
treatments 2-4 were fed the high fat diet. Mice in treatment 2-4 were fed the high fat 
diet for the rest of the experiment. Similarly, for the week 6 and week 12 time points, 
the UVR and other skin treatments were administered at ZT3 (9am) (Table 2.2). 
Interscapular skin temperature was first measured, followed by blood glucose levels and 
then UCP-1 bioluminescence quantified in iBAT using the IVIS bioimager. This order 
was selected as our preliminary investigations suggested that the process of 
anaesthetising mice for imaging affected both measures for up to one-hour post-




Table 2.2: Outline of the times data was collected during the circadian analyses. At baseline, 
week 6 and week 12 of the experiment described in Figure 2.1, interscapular skin temperature, 
blood glucose and UCP-1 expression (in that order) were measured at the following times, with 










2.8.1 Measuring interscapular skin temperature 
Interscapular skin temperature of the shaved skin region (neck-upper back skin over the 
iBAT deposit) was measured using a forehead thermometer (Chemist Warehouse, 
Australia). A mean of three recordings was obtained at each time point (Table 2.2).  
 
2.8.2 Measuring blood glucose 
During each circadian study, at baseline (ZT1), a 1 cm portion of the end of each mouse 
tail was removed using a sterile scalpel blade 23 (Swann-Morton, England), with a 
droplet of blood collected onto a glucose strip (AccuChek Performa, Roche, Castle Hill, 
NSW Australia) and inserted into a glucometer (AccuChek Performa) to measure blood 
glucose. At all other ZT (Table 2.2), the scab from the initial wound was removed, or a 
small cut was made (if necessary) to remove a 1mm section of the end of the tail, using 
a scalpel blade.  
 
Z-time Time of the day 
ZT1 7am 








2.8.3 Measuring UCP-1 bioluminescence  
As described above, UCP-1 expression was quantified in iBAT at 4-6 hourly intervals 
over 28 hours at week 0 (baseline), week 6 and week 12 (Table 2.2). The UCP-1 
luciferase mouse allows us to use luciferase activity as a marker for UCP-1 protein 
expression given that the luciferase gene was inserted in the initiation codon of the 
UCP-1-coding sequence, as validated previously(215,389). Mice were anaesthetised 
using isofluorane with UCP-1 expression was quantified by measuring the extent of 
bioluminescence at iBAT site, following the injection of the UCP-1 luciferase 
transgenic mice with luciferin. Living Image software (v4.2, Perkin Elmer, 
Massachusetts, USA) was used to record the UCP-1 specific bioluminescence in 
anaesthetised mice along with the IVIS Spectrum Bioimager (Perkin Elmer, 
Massachusetts, USA). At each Z-time, measurements were performed on 5 mice using 
the ‘D’ manifold (5 mice per run), with a control female mouse included to record 
background bioluminescence over a maximum of 2.5 hours (during one timepoint).  
 
Mice were first placed in the anaesthesia chamber (with isoflurane) and once sedated, 
200 L of D-luciferin (15 mg/mL in PBS, Perkin Elmer, Massachusetts, USA) was 
injected (intraperitoneally) into anaesthetized mice. Mice were then placed into the IVIS 
manifold chamber, on the stage, which was  maintained at 37 C. Living Image 
software was used to acquire bioluminescence as a time series of 6 segments, with 
exposure time of 3 minutes per segment (total of 18 min per run), with a subject height 
of 0.7 cm, and default binning (4 pixels per bin) and f/stop (1) settings. After data was 
collected, the amount of bioluminescence was measured as radiance by setting regions 
of interest around the iBAT region, with the peak radiance recorded for the 18 minutes 




2.9 Measuring body weight and weight gain 
All mice were weighed weekly from 7 weeks of age. Mice were weighed every Friday 
between 9 and 10.30am, using digital scales (CAS MWP-3000H, >0.05g sensitivity). 
Percentage weight gain was calculated from 8 weeks of age (experimental baseline), 
using the following equation: 
% 𝑊𝑒𝑖𝑔ℎ𝑡 𝑔𝑎𝑖𝑛 = 100




Figure 2.4: Peak UCP-1 expression quantification in interscapular brown adipose tissue. 
UCP-1 luciferase transgenic male mice were injected with 200 L (intraperitoneally) of D-
luciferin and peak UCP-1 radiance was measured and quantified via the IVIS Spectrum 
system. A series of 6 images were captured at 3 min intervals were taken immediately after 
all mice were injected with the D-lucferin (n=5 mice per run). The peak of UCP-1 expression 
was quantified for each mouse after measuring bioluminescence at 3, 6, 9, 12, 15 and 18 
minutes post-luciferin injection. The graph shows the average radiance (p/s/cm2/sr) with 




2.10 Measuring signs of type-2 diabetes 
Signs of type-2 diabetes were evaluated in mice for whom the circadian rhythms of 
UCP-1 expression (bioluminescence) was not assessed (n=8/treatment). This was done 
to limit stress experienced by each animal, as each circadian analysis of UCP-1 
expression in iBAT required mice to undergo 7 lots of 20 min anaesthesia in a relatively 
short 28-hours timeframe. Signs of type-2 diabetes that were measured included: fasting 
insulin (Section 2.10.1), fasting glucose (Section 2.10.2), glucose intolerance (via 
glucose tolerance test, GTT, Section 2.10.3) and insulin sensitivity (via an insulin 
tolerance test, ITT, Section 2.10.4). 
 
2.10.1 Measuring insulin levels in plasma 
 
2.10.1.1 Collecting blood 
At 17 weeks of age (9 weeks of dietary and skin interventions, Figure 2.1), plasma from 
fasting mice (n=8/treatment) was collected in which insulin concentrations were 
measured. Mice were placed in a new cage with bedding and water and fasted for five 
hours prior to collecting blood. Mice were then placed under a heat lamp for 3 min to 
allow dilation of blood vessels in the tail. A sterile scalpel blade was used to nick the 
lateral tail vein, and ~100L of blood collected into a K2EDTA-coated tube (BD 
Vacutainer, Oakville, USA). Ferric chloride, a haemostat, (ProVet, Perth Australia) was 
used to cauterise the wound on the tail if required.  
 
2.10.1.2 Extracting plasma from blood 
Blood was stored on ice during transportation and plasma separated following the 
centrifugation of samples for 10 minutes at 2,000xg (Eppendorf Centrifuge 5415R, 
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Germany). Plasma was carefully aliquot into a 1.5 ml polypropylene tube and stored at -
80 C until required for testing.  
 
2.10.1.3 Measuring insulin in plasma using ELISA 
Insulin concentrations were measured in plasma (10µL) according the instructions of a 
commercially available ELISA kit (Rat/Mouse EZRMI-13K; EMD Millipore, Missouri, 
USA), with the final colormetric reaction measured at 450nm and 590nm on the 
EnSpire plate reader (Perkin Elmer) with TIBCO Spotfire software (Perkin Elmer). The 
difference between absorbance values was determined, and the concentrations of insulin 
were interpolated using a 5-parametric logistic (r=0.999) standard curve constructed 
from the readings of the standards. The 5-parameteric logistic standard curve was 
plotted using Microsoft Excel (Microsoft, Washington, USA) All quality controls fell 
within the range specified by the manufacturer, and limit of detection of the assay was 
≤0.1 ng/mL of insulin. 
 
2.10.2 Measuring fasting glucose levels in blood 
Fasting blood glucose levels were measured at baseline prior to the GTT and ITT 
performed as described in Section 2.10.3 below. 
 
2.10.3 Glucose and insulin tolerance tests 
GTT and ITT were performed in mice at 18 and 19 weeks of age (at week 10 and 11 of 
the dietary and skin interventions, Figure 2.1), respectively. Mice were placed into a 
new cage with bedding and water and fasted for five hours prior to each test. Baseline 
fasting blood glucose levels were measured (prior to injection of glucose or insulin) by 
removing a 1 mm portion of the end of the tail using a sterile scalpel blade-23 (Swann-
Morton, England). A drop of blood was collected onto a glucose strip (AccuChek 
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Performa) and inserted into a glucometer (AccuChek Performa) for measurement of 
blood glucose. For the GTT and ITT, glucose (1g/kg) or insulin (0.9IU/kg) 
(respectively) was injected interperitoneally in 200 µl of 0.9% saline (Baxter, Australia) 
using a 27-gauge insulin needle (Terumo, USA). Blood glucose levels were measured at 
15, 30, 45, 60, 90 and 120 minutes post-injection.  
 
2.11 Endpoint blood and tissue collection 
At the end of the experiment (12 weeks into study, in 20-week-old mice) blood and 
liver, gWAT, iBAT tissues were collected from euthanized mice (n=20/treatment), 
approximately 24 hours after the final skin treatments.  
 
2.11.1 Cardiac puncture to collect blood  
Cardiac puncture was performed to collect blood. Mice were anaesthetised using 1mL 
of methoxyflurane (Medical Developments International Ltd., Springvale, Australia) in 
a glass jar (in tissues). A 25G needle (attached to a 1mL syringe) (Terumo, Japan) was 
used to pierce the chest cavity into the heart with at least 0.5mL of blood collected per 
mouse. Blood was transferred into a fresh 1.5mL polypropylene tube (Eppendorf, 
Germany). Post cardiac puncture, mice were humanly euthanised via cervical 
dislocation.  
 
2.11.2 Separation of serum from blood 
Blood collected via cardiac puncture was allowed to clot at room temperature for 1 hour 
and centrifuged at 2000xg for 10 min (Eppendorf Centrifuge 5415R, Germany). Serum 
was removed into a new 1.5mL polypropylene tube (Eppendorf) and stored at -80C. 
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2.11.3 Tissue collection 
Livers, iBAT, gWAT were collected from all mice (n=20/treatment) and weighed using 
a fine electronic balance (Ohaus Analytical Standard, New Jersey, USA, >0.0001g 
sensitivity).  
2.12 Liver histopathology  
Livers were fixed (n=5/treatment) in 10% buffered formalin (in PBS; Sigma-Aldrich) 
overnight. Liver samples were then rinsed once with 0.9% saline (0.9% Sodium 
chloride for irrigation, Baxter, Deerfield, USA) and stored in 0.9% saline at 4C. Liver 
tissue was processed and embedded in paraffin using standard successive dehydration 
and clearing steps requiring ethanol and xylene as specified by manufacturer’s 
instructions of the Leica Tissue Processor ASP300S (Leica Microsystems, Victoria, 
Australia). Embedded liver tissue was set in paraffin in moulds and sectioned using 
Leica RM2235 Microtome (Leica, Nussloch, Germany) onto Superfrost Plus charged 
microscope slides (Thermo Fisher Scientific, Waltham, Massachusetts, USA). Liver 
sections were stained with Haematoxylin and Eosin (H&E) stain or Masson’s trichrome 
stain using the Lecia ST5010 Autostainer XL (Leica Microsystems). Each liver section 
was scored in a blinded fashion in accordance with a modified version of the non-
alcoholic steatohepatitis scoring system (developed by Clinical Research Network 
(395,396). Three criteria were used to assess the extent of NAFLD, including: 
hepatocellular ballooning and steatosis (from H&E stain), and fibrosis (from Masson’s 




Table 2.3 depicts the non-alcoholic steatohepatitis scoring system used to score the 
stained livers(396). The mean score for each criterion was determined by averaging the 
score over 5 fields of view of each liver section. The scores for each criterion were 
added together to calculate a total mean score (out of 10) as a measure of the extent of 
NAFLD observed in each mouse.  
  
Figure 2.3: Representative images of liver sections stained with H&E and Masson’s trichrome 
stain. A representative image of liver section stained with H&E a) mice fed a low fat diet (LFD) 
and b) mice fed a high fat diet and stained with Masson’s trichrome: c) mice fed a LFD and d) 
mice fed a HFD. Images taken at 20x magnification with oil.  
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Table 2.3: Non-alcoholic steatohepatitis scoring system. The criteria for this scoring system 
was developed by the Clinical Research Network(396), with a score out of ten determined by 
adding scores for hepatocellular ballooning, steatosis and fibrosis together. 
 
Hepatocellular ballooning  
(scored out of 3): 
Steatosis  
(scored out of 3): 
Fibrosis  
(scored out of 4):  
0 = no ballooning 
 
0 = < 5 % 0 = no fibrosis  
1 = little ballooning 1 = 5 % - < 33 % 1 = fibrosis in some portal 
areas 
2 = much ballooning 2 = < 33 % - < 66 % 2 = fibrosis in most portal 
areas 
3 = most with ballooning 3 = > 66 % 3 = fibrosis in most portal 
areas with portal-portal 
bridging 
  4 = fibrosis in all portal areas 
with portal-portal bridging 
 
 
2.13 Statistical analyses 
All values are expressed as mean  SEM. All data collected during this study was 
imported into and analysed using Microsoft Excel (Version 16.16.3, 2018) and 
GraphPad Prism (Version 7.0, 2016, California, USA). The results of both experiments 
were combined as per previously published studies(1,102). The combined results were 
not statistically different which allowed a sufficient power to measure the UCP-1 
expression in the iBAT of mice (n=12/treatment). Area under the curve (AUC) analyses 
was conducted for GTT and ITT, using zero as the baseline (Prism 7.0). All data was 
tested for normal distribution using the student t test(s) and 2-way ANOVA tests. Data 
was subjected to ROUT analysis to identify outliers (Q=1%), which were removed prior 
to further statistical analyses. Descriptive statistics of all variable were reported as mean 
and standard error of the mean (SEM)..For body weight, weight gain, tissue weights, 
fasting insulin, fasting glucose and NAFLD histopathology variables, one-way Analysis 
of Variance (ANOVA, in GraphPad Prism 7.0) was used to compare the effects of each 
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treatment group with a Tukey’s post-hoc analysis used to define the differences between 
treatment groups.  
 
2.13.1 UCP-1 bioluminescence in iBAT 
To determine the peak UCP-1 bioluminescence in the iBAT site, an AUC analysis was 
performed (GraphPad Prism). Data was compared at each time point over the 28 hours 
of measurements at baseline and after 6 and 12 weeks of dietary and skin interventions, 
using a two-way ANOVA to determine the effect of Z-time on each treatment and to 
compare between treatments at each timepoint.  
 
2.13.2 Cosinor analysis  
Cosinor analysis was used to measure the rhythmicity in the following daily profiles 
done at the baseline, 6 and 12 weeks timepoints of the experiment, whereby UCP-1 
expression in iBAT, blood glucose and interscapular skin temperature were measured at 
4-6 hourly intervals for 28 hours. This was achieved using a non-linear regression 
analysis in GraphPad Prism, using the following equation:  
𝑦 = 𝑚𝑒𝑠𝑜𝑟 + 𝑎𝑚𝑝𝑙𝑖𝑡𝑢𝑑𝑒 ∗ cos((2 ∗
𝑐(𝜋)
24
∗ 𝑍𝑇 − 𝑎𝑐𝑟𝑜𝑝ℎ𝑎𝑠𝑒) 
 
Cosinor analysis are used to derive classic circadian rhythm features of mesor, 
amplitude and acrophase for each daily profile (Figure 2.4). The coefficient of 
determination (r2) was used as an index of cosinor rhythmicity and daily profiles were 
considered ‘rhythmic’ or a ‘trend’ if their fit to cosine function was significant (p<0.05) 





Figure 2.4: Cosine curve features. Representation of the typical cosine curve features, 
mesor (rhyhm adjusted mean), amplitude (the difference between the mesor and the 
rhythm peak) and acrophase (the time of the rhythm peak).  
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This circadian study was carried out over 12 weeks, in two batches, which were 
staggered by a week. During each of the three circadian analyses (baseline, week 6 and 
week 12), UCP-1 bioluminescence, blood glucose level and interscapular skin 
temperature were measured at 4-6 hourly intervals over 28 hours. The UCP-1 transgenic 
male mice were exposed to 1 of 4 treatments (see also Figure 2.1): 
1. Fed a low fat diet, and mock-irradiated twice a week (negative control, n=20); 
2. Fed a high fat diet, and mock-irradiated twice a week (positive control, n=20); 
3. Fed a high fat diet, and exposed to low dose UVR (1kJ/m2) twice a week (n=20); or, 
4. Fed a high fat diet and exposed to low dose UVR (1kJ/m2) and topically treated with 
the nitric oxide scavenger, cPTIO (1mmol), twice a week (n=20).  
 
The circadian data is presented first in this chapter followed by the metabolic outcomes 
pf body weight, weight gain, tissue weights, liver histopathological scores, and finally 
signs of type-2 diabetes.  
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3.2 Circadian measures 
At baseline (week 0), week 6 and 12, circadian measurement of UCP-1 expression in 
iBAT, glucose concentrations in blood, and interscapular skin temperature were 
measured over 28 hours in UCP-1 luciferase transgenic mice (see Section 2.8), with 
data collected over 28 hours as per Table 2.2. At each timepoint, mice were exposed to 
low dose UVR (1kJ/m2) or mock-irradiated at ZT3 (9 am), with immediate topical 
treatment with vehicle (Treatments 1-3) or cPTIO (Treatment 4) (see Figure 2.1).  
 
3.2.1 UCP-1 expression in interscapular BAT. 
Mice fed a low fat diet exhibited significantly increased UCP-1 levels 
(bioluminescence) in iBAT at weeks 6 and 12 compared to baseline. However, this 
increase was significantly lower when compared to the increase in UCP-1 levels 
measured in the iBAT of mice fed a high fat diet. At baseline, UCP-1 expression in 
iBAT was not significantly modified over the 28 hours for mice in any treatment 
(Figure 3.1a). Similarly, after 6 weeks of treatment, there was no significant variation in 
the expression level of UCP-1 in iBAT; however, at week 6 mice fed a high fat diet had 
a significantly increased UCP-1 expression in iBAT at ZT27, compared to mice fed the 
low fat diet (Figure 3.1b). At week 12, mice fed a high fat diet had a significantly 
increased UCP-1 expression in iBAT at ZT1, ZT5, ZT17, ZT23 and ZT27 compared to 
mice fed a low fat diet (Figure 3.1c). UCP-1 expression in the iBAT of mice fed a high 
fat diet was also significantly increased compared to that measured in mice fed a high 
fat diet exposed to UVR at ZT27 (Figure 3.1c), which was 24 hours following exposure 
to UVR (at ZT3).  
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Figure 3.1: Mean peak radiance of UCP-1 bioluminescence measured at 7 timepoints over 
28 hours at baseline (week 0), week 6 and 12 weeks of treatment. UCP-1 luciferase 
transgenic mice were fed a low fat diet (LFD) for 4 weeks of age until 8 weeks of age and then 
separated into one of the four treatment groups, in which mice were: 1. fed a LFD; 2. fed a 
high fat diet (HFD); 3. fed a HFD with ongoing ultraviolet radiation (UVR) exposure twice a 
week; or, 4. fed a HFD with ongoing UVR exposure twice a week followed by immediate 
topical treatment of exposed skin with cPTIO (0.1mmol, UVR + cPTIO), for 12 weeks. At (a) 
baseline (week 0), and after (b) 6 and (c) 12 weeks of treatment. Peak UCP-1 radiance was 
measured in iBAT every 4-6 hours at 7 time points in 28 hours. The broken green line 
represents UVR exposure done at ZT3. Data is presented as mean  SEM (n=12 per treatment 
group, *p<0.05 HFD v LFD, #p<0.05 HFD v UVR, two-way ANOVA with Tukey’s post-hoc 
analysis).  
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3.2.3 Blood levels of glucose  
Similar to UCP-1 expression in iBAT, no significant difference in blood glucose levels 
was observed throughout the 28 hours of circadian analysis, or between treatment 
groups at baseline (week 0) (Figure 3.2a). At week 6, mice fed a low fat diet had a 
reduced blood glucose levels at ZT5 and ZT9 compared to mice fed a high fat diet 
(Figure 3.2b). At week 12, mice fed a low fat diet had significantly reduced blood 
glucose levels compared to mice fed a high fat diet at ZT5, ZT9, Z17-ZT27 (Figure 
3.2c). No significant differences were observed between mice fed a high fat diet and 
those exposed to low dose UVR with and without cPTIO administration.  
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Figure 3.2: Blood glucose levels measured at 7 timepoints over 28 hours, at week 0, week 
6 and week 12 of the treatment. UCP-1 luciferase transgenic mice were fed a low fat diet 
(LFD) for 4 weeks of age until 8 weeks of age. Mice were then separated into one of the four 
treatment groups, in which mice were: 1. fed the LFD; 2. fed a high fat diet (HFD); 3. fed a 
HFD with ongoing ultraviolet radiation (UVR) exposure twice a week; or, 4. fed a HFD with 
ongoing UVR exposure twice a week followed by immediate topical treatment of exposed 
skin with cPTIO (0.1mmol, UVR + cPTIO), for 12 weeks. At (a) baseline (week 0), and after (b) 
6 and (c) 12 weeks of treatment, blood glucose levels in were quantified every 4-6 hours 
over a 28 hours. The broken green line represents UVR exposure done at ZT3. Data are 
presented as mean  SEM (n=20 per treatment group, *p<0.05 HFD v LFD, two-way ANOVA 
with Tukey’s post-hoc analysis). 
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3.2.3 Interscapular skin temperature  
At baseline, mice fed a high fat diet had a significantly reduced interscapular skin 
temperature compared to mice fed a high fat diet and exposed to UVR at ZT23 (Figure 
3.3a). At week 6, mice fed a high fat diet had increased interscapular skin temperature 
compared to mice fed the low fat diet at ZT13 and ZT27. Mice fed a high fat diet with 
ongoing UVR exposure followed by topical treatment with cPTIO had increased 
interscapular skin temperature compared to mice exposed to UVR at ZT13 (Figure 
3.3b). Moreover, at ZT13 mice fed a high fat diet (only) had markedly increased 
interscapular skin temperature compared to mice fed a low fat diet and mice with 
ongoing UVR treatment. At week 12, mice fed a low fat diet had significantly reduced 
interscapular skin temperature compared to mice fed a high fat diet at ZT23. 
Additionally, mice fed a high fat diet with ongoing UVR exposure had significantly 
reduced interscapular skin temperature compared to mice exposed to ongoing UVR and 





Figure 3.3: Interscapular skin temperature measued at 7 timepoints over 28 hours at week 
0, week 6 and week 12 of the study. UCP-1 luciferase transgenic mice were fed a low fat 
diet (LFD) for 4 weeks of age until 8 weeks of age. Mice were then separated into one of the 
four treatment groups, in which mice were: 1. fed the LFD; 2. fed a high fat diet (HFD); 3. fed 
a HFD with ongoing ultraviolet radiation (UVR) exposure twice a week; or, 4. fed a HFD with 
ongoing UVR exposure twice a week followed by immediate topical treatment of exposed 
skin with cPTIO (0.1mmol, UVR + cPTIO), for 12 weeks. At (a) baseline (week 0), and after (b) 
6 and (c) 12 weeks of treatment, interscapular skin temperature was measured every 4-6 h 
times over 28 hours. The broken green line represents UVR exposure done at ZT3. Data are 
presented as mean  SEM (n=20 per treatment group, *p<0.05 HFD v LFD, #p<0.05 HFD v 
UVR and ^p<0.05 UVR v cPTIO, two-way ANOVA with Tukey’s post-hoc analysis). 
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3.2.4 Cosinor analyses  
Cosinor analysis was carried out to determine the rhythmicity in the three variables 
(UCP-1 expression, interscapular skin temperature and blood glucose levels) recorded 
in the circadian analysis as per Section 2.13.2.  
 
3.2.4.1 UCP-1 expression in interscapular BAT 
There was no significant cosinor rhythm observed in UCP-1 expression in iBAT for 
mice of any treatment group at baseline, week 6 or week 12 (Table 3.1).  
 
3.2.4.2 Blood glucose levels 
At baseline, in mice fed a high fat diet exposed to UVR there was a trend (p=0.06) for 
cosinor rhythmicity in blood glucose levels (Table 3.1). No other (near) significant 
cosinor rhythms were observed at baseline, week 6 or 12 for mice of any treatment 
group (Table 3.1).  
 
3.2.4.3 Interscapular skin temperature 
Cosinor rhythmicity was not observed in interscapular skin temperature measured in 
mice during baseline and week 6 (Table 3.1). At week 12, there was some evidence for 
cosinor trends in rhythmicity in interscapular skin temperature measured in mice fed a 
high fat diet (p= 0.064), and mice exposed to UVR with cPTIO treatment (p=0.059) 




 Week 01 Week 6 Week 12 
 LFD HFD UVR UVR + 
cPTIO 
LFD HFD UVR UVR + 
cPTIO 
LFD HFD UVR UVR + 
cPTIO 










































































1UCP-1 luciferase transgenic mice were fed a low fat diet (LFD) for 4 weeks of age until 8 weeks of age. Mice were then separated into one of the four treatment groups, in which mice were: 1. fed the 
LFD; 2. fed a high fat diet (HFD); 3. fed a HFD with ongoing ultraviolet radiation (UVR) exposure twice a week; or, 4. fed a HFD with ongoing UVR exposure twice a week followed by immediate topical 
treatment of exposed skin with cPTIO (0.1mmol, UVR + cPTIO). At baseline (week 0, prior to treatments starting), and after 6 and 12 weeks of treatments, with consinor R2 and associated p-values 
shown in brackets. Boxes in highlghted represent significant trends (0.05>p>0.1) observed for that variable.  
 




All mice exhibited increased expression of UCP-1 in iBAT with age; however, mice fed 
a high fat diet had significantly increased UCP-1 levels in iBAT by week 12, compared 
to mice fed a high fat diet. At week 12, in mice fed a high fat diet with ongoing UVR 
exposure, there was reduced the UCP-1 expression in iBAT 24 hours post UVR 
treatment, compared to mice fed a high fat diet. No significant difference was observed 
in UCP-1 levels in iBAT of mice with or without cPTIO treatment post-UVR exposure. 
A significant cosinor rhythm in UCP-1 levels in iBAT was not observed at any time-
point in any treatment. 
 
Mice fed a high fat diet had increased blood glucose levels compared to mice fed a low 
fat diet at various times during the circadian measures done at week 6 and 12. There 
was no effect of UVR exposure (with or without cPTIO treatment) on blood glucose 
levels in mice fed a high fat diet.. A significant cosinor rhythm in blood glucose levels 
was not observed at any time-point in any treatment. 
 
Finally, mice fed a high fat diet had increased interscapular skin temperatures at week 6 
compared to mice fed a low fat diet (at ZT13 and ZT27), and mice fed a high fat diet 
with ongoing UVR (at ZT13). Mice with cPTIO treatment post UVR exposure also had 
a higher interscapular skin temperature compared to mice exposed to UVR without 
cPTIO administration at ZT13 in week 6. At week 12, mice with cPTIO treatment had 
higher interscapular skin temperature compared to mice without cPTIO treatment. A 
significant cosinor rhythm in interscapular skin temperature was not observed at any 
time-point in any treatment. 
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3.3 Metabolic Outcomes 
 
3.3.1 Measures of weight gain and adiposity 
 
3.3.1.1 Body weight 
Mice were weighed weekly with body weights shown in Figure 3.4. A reduction in 
body weight was observed immediately after each intensive circadian study. Mice fed a 
high fat diet had significantly increased (p<0.02) body weight compared to mice fed a 
low fat diet from week 1 until week 12 (end of experiment) (Figure 3.4b). No 
significant differences were observed in the body weights of mice fed a high fat diet 
compared to mice with ongoing exposure to UVR (Figure 3.4c). There was no 
difference in body weights observed for mice exposed to UVR with and without 
treatment with cPTIO (Figure 3.4d). 
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Figure 3.4: Body weight of 
experimental mice throughout 
study. UCP-1 luciferase transgenic 
mice were fed a low fat diet (LFD) 
for 4 weeks of age until 8 weeks of 
age. Mice were then separated into 
one of the four treatment groups, in 
which mice were: 1. fed the LFD; 2. 
fed a high fat diet (HFD); 3. fed a 
HFD with ongoing ultraviolet 
radiation (UVR) exposure twice a 
week; or, 4. fed a HFD with ongoing 
UVR exposure twice a week 
followed by immediate topical 
treatment of exposed skin with 
cPTIO (0.1mmol, UVR + cPTIO), for 
12 weeks. Body weights were 
recorded weekly throughout the 
experiment, comparing (a) all 
treatment groups, (b) for mice fed a 
LFD or HFD, (c) for mice fed a HFD 
with and without UVR exposure and 
(d) mice fed a HFD with UVR 
exposure or without topical 
treatment of cPTIO. All data is 
presented as mean  SEM (n=20 per 
treatment group, *p<0.05 relative 
to HFD v LFD, one-way ANOVA with 
Tukey’s post hoc analysis at each 
time point). Dotted lines indicated 
the timing of the circadian study, 





3.3.1.2 Weight gain 
Mice were weighed weekly with percentage weight gain calculated from when the 
experiment began (at 8 weeks of age, baseline). Weight gain is shown in Figure 3.5. A 
reduction in weight gain was observed immediately after each intensive circadian study. 
Mice fed a high fat diet had significantly increased weight gain compared to mice fed a 
low fat diet from week 1 until the end of experiment (Figure 3.5b). No significant 
difference was observed in weight gain between mice fed a high fat diet, compared to 
mice with exposed to UVR (Figure 3.5c). Similarly, there were no differences in weight 
gain observed between mice fed a high fat diet exposed to UVR with,or without cPTIO 
treatment at any time throughout the 12 weeks (Figure 3.5d).  
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Figure 3.5: Weight gain for 
experimental mice throughout study. 
UCP-1 luciferase transgenic mice 
were fed a low fat diet (LFD) for 4 
weeks of age until 8 weeks of age. 
Mice were then separated into one of 
the four treatment groups, in which 
mice were: 1. fed the LFD; 2. fed a 
high fat diet (HFD); 3. fed a HFD with 
ongoing ultraviolet radiation (UVR) 
exposure twice a week; or, 4. fed a 
HFD with ongoing UVR exposure twice 
a week followed by immediate topical 
treatment of exposed skin with cPTIO 
(0.1mmol, UVR + cPTIO), for 12 weeks. 
Weight gain were determined weekly 
(compared to that measured at 
baseline) throughout the experiment, 
comparing (a) all treatment groups, (b) 
mice fed a LFD or HFD, (c) mice fed a 
HFD with and without UVR exposure 
and (d) mice fed a HFD with UVR 
exposure or without topical treatment 
of cPTIO. All data is presented as mean 
 SEM (n=20 per treatment group, 
*p<0.05 relative to HFD only, one-way 
ANOVA, using Tukey’s post-hoc 
analysis used to define differences 
between treatments at each time 
point). Dotted lines indicated the 
timing of the circadian study, which 
was also performed at baseline. 
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3.3.1.3 Weight of gonadal white adipose tissue 
Mice fed a low fat diet had significantly reduced (p<0.0001) gonadal white adipose 
tissue compared to mice fed a high fat diet (Figure 3.6). Mice fed a high fat diet had 
significantly increased (p<0.005) gonadal white adipose tissue weight compared to mice 
fed a high fat diet with ongoing UVR exposure (Figure 3.6). No significant difference in 
gonadal white adipose tissue weights were observed between mice exposed to UVR 
with and without topical cPTIO (Figure 3.6).  
 
Figure 3.6: Gonadal white adipose tissue weights. UCP-1 luciferase transgenic mice were fed 
a low fat diet (LFD) for 4 weeks of age until 8 weeks of age. Mice were then separated into 
one of the four treatment groups, in which mice were: 1. fed the LFD; 2. fed a high fat diet 
(HFD); 3. fed a HFD with ongoing ultraviolet radiation (UVR) exposure twice a week; or, 4. fed a 
HFD with ongoing UVR exposure twice a week followed by immediate topical treatment of 
exposed skin with cPTIO (0.1mmol, UVR + cPTIO), for 12 weeks. Weights of interscapular 
brown adipose tissue deposits at 12 weeks post treatment (when mice were 20 weeks of age) 
are shown, with data presented as mean  SEM (n=20 per treatment group, *p<0.05 using a 
one-way ANOVA with Tukey’s post-hoc analysis). 
 
 




















3.3.1.4 Weight of interscapular brown adipose tissue 
Mice fed a high fat diet had significantly increased (p<0.05) iBAT weights compared to 
mice fed a low fat diet, and mice exposed to UVR (Figure 3.7). There was no 
significance difference in iBAT weights observed between mice exposed to UVR with 




Figure 3.7: Interscapular brown adipose tissue weights. UCP-1 luciferase transgenic mice 
were fed a low fat diet (LFD) for 4 weeks of age until 8 weeks of age. Mice were then 
separated into one of the four treatment groups, in which mice were: 1. fed the LFD; 2. fed 
a high fat diet (HFD); 3. fed a HFD with ongoing ultraviolet radiation (UVR) exposure twice a 
week; or, 4. fed a HFD with ongoing UVR exposure twice a week followed by immediate 
topical treatment of exposed skin with cPTIO (0.1mmol, UVR + cPTIO), for 12 weeks. 
Weights of interscapular brown adipose tissue deposits at 12 weeks post treatment (when 
mice were 20 weeks of age) are shown, with data presented as mean  SEM (n=20 per 
























3.3.1.5 Summary: Measures of weight gain and adiposity 
Mice fed a high fat diet (only) had increased weight gain and body weight compared to 
mice fed a low fat diet from week 1 into the study until the end. No significant effects of 
UVR exposure, with or without cPTIO, were evident on the body weight and weight 
gain; however, these mice did have increased body weight and weight gain compared to 
mice fed the low fat diet. Additionally, both mice fed a low fat diet and mice with 
ongoing UVR exposure (only) had reduced gonadal WAT and iBAT tissue weights 
compared to both mice fed a high fat diet.  
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3.3.2 Measures of non-alcoholic fatty liver disease and type-2 diabetes  
 
3.3.2.1 Signs of non-alcoholic fatty liver disease 
At the end of each experiment, liver samples were weighed as described in Section 2.12. 
The extent of liver histopathology (steatosis, ballooning and fibrosis) was determined as 
described in Section 2.12 and Table 2.2(396). Liver specimens were scored for 
steatosis, hepatocellular ballooning and fibrosis to measure signs of NAFLD.  
 
3.3.2.1.1 Liver weight 
No significant difference was observed in the liver weights between mice of any 
treatment (Figure 3.8).  
 
 
Figure 3.8: Liver weights. UCP-1 luciferase transgenic mice were fed a low fat diet (LFD) for 
4 weeks of age until 8 weeks of age. Mice were then separated into one of the four 
treatment groups, in which mice were: 1. fed the LFD; 2. fed a high fat diet (HFD); 3. fed a 
HFD with ongoing ultraviolet radiation (UVR) exposure twice a week; or, 4. fed a HFD with 
ongoing UVR exposure twice a week followed by immediate topical treatment of exposed 
skin with cPTIO (0.1mmol, UVR + cPTIO), for 12 weeks. Liver weights measured at 12 weeks 
post treatment (when mice were 20 weeks of age) are shown, with data presented as mean 
 SEM (n=20 per treatment group, using a one-way ANOVA with Tukey’s post-hoc analysis). 
 


















3.3.2.1.2 Liver histopathology 
Liver sections stained with H&E or Masson’s trichrome, from data from representative 
mice of each treatment shown in Figure 3.9. The extent of liver histopathology was 
significantly greater (p<0.0001) in mice fed a high fat diet compared to mice fed a low 
fat diet, or, mice fed a high fat diet and exposed to UVR (Figure 3.10). Mice fed a high 
fat diet with ongoing exposure to UVR topically treated with cPTIO had significantly 
increased (p<0.0001) histopathological scores compared to mice fed a high fat also 
exposed to UVR only (Figure 3.10). Liver histopathology in mice fed a high fat diet 
was largely due steatosis and hepatocellular ballooning, with few signs of fibrosis (see 
Figure 3.10).  
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Figure 3.9: Liver sections stained with H&E (a-d) and Masson’s trichrome (e-f). UCP-1 
luciferase transgenic mice were fed a low fat diet (LFD) for 4 weeks of age until 8 weeks of age. 
Mice were then separated into one of the four treatment groups, in which mice were: 1. fed 
the LFD; 2. fed a high fat diet (HFD); 3. fed a HFD with ongoing ultraviolet radiation (UVR) 
exposure twice a week; or, 4. fed a HFD with ongoing UVR exposure twice a week followed by 
immediate topical treatment of exposed skin with cPTIO (0.1mmol, UVR + cPTIO) for 12 weeks.  
After 12 weeks of treatment, liver samples were histologically processed, paraffin embedded, 
with sections stained with H&E (a-d) or Masson’s trichrome (e-h). Representative sections of 
livers from mice of the (a, e) LFD, (b, f) HFD, (c, g) UVR, and (d, h) UVR + cPTIO treatment 
groups are shown at x20 magnification with oil. Black arrows point to signs of fibrosis, green 





Figure 3.10: Liver histopathological scores. UCP-1 luciferase transgenic mice were fed a 
low fat diet (LFD) for 4 weeks of age until 8 weeks of age. Mice were then separated into 
one of the four treatment groups, in which mice were: 1. fed a low fat diet (LFD); 2. fed a 
high fat diet (HFD); 3. fed a HFD with ongoing ultraviolet radiation (UVR) exposure twice a 
week; or, 4. fed a HFD with ongoing UVR exposure twice a week followed by immediate 
topical treatment of exposed skin with cPTIO (0.1mmol, UVR + cPTIO), for 12 weeks. After 
12 weeks of treatment, liver samples were histologically processed, paraffin embedded, 
with sections stained with H&E or Masson’s trichrome, as shown in Figure 3.10. A combined 
histopathology score for signs of non-alcoholic fatty liver disease was determine for each 
liver, in which a total score (/10) combined the extent of steatosis (/3), hepatocellualr 
ballooning (/3) and fibrosis (/4) observed. All data are shown as mean  SEM (n=5 per 
treatment, *p<0.05 using one-way ANOVA, with Tukey’s post-hoc analysis).  
 


























3.3.2.2 Signs of type-2 diabetes 
Fasting blood was collected in week 9 of the experiment to assess fasting insulin levels 
in plasma (Section 2.10.1). Fasting blood glucose levels were measured at week 10 
while conducting the GTT (Section 2.10.2). The ITT was done at week 11 of the 
experiment (Section 2.10.2).  
 
3.3.2.2.1 Fasting plasma insulin levels 
No significant difference in fasting levels of plasma insulin was observed between mice 
of any treatment group at week 9 of the experiment (Table 3.2).  
 
Table 3.2: Signs of type-2 diabetes 
 Treatment group1 
 LFD HFD UVR UVR + cPTIO 
Fasting plasma insulin2 
(ng/mL) 1.98  0.51 3.01  0.62 3.15  1.07 3.05  0.84 
Fasting blood glucose3 
(mmol/L) 8.40  0.31 9.08  0.39 8.55  0.29 9.29  0.37 
AUC of GTT3 1510  80 1460  80 1624  75.5 1690  145 
AUC of ITT3 720.4  60.7 873  108 859 89 818  61 
1UCP-1 luciferase transgenic mice were fed a low fat diet (LFD) for 4 weeks of age until 8 weeks of age. 
Mice were then separated into one of the four treatment groups, in which mice were: 1. Fed the LFD; 2. 
fed a high fat diet (HFD); 3. fed a HFD with ongoing ultraviolet radiation (UVR) exposure twice a week; 
or, 4. fed a HFD with ongoing UVR exposure twice a week followed by immediate topical treatment of 
exposed skin with cPTIO (1mmol, UVR + cPTIO), for 12 weeks.  
2Fasting serum insulin levels were measured at at week 9.  
3Fasting blood glucose was measured at week 10, immediately prior to conducting the glucose tolerance 
test (GTT). Data is also shown for the area under the curve (AUC) of the GTT and insulin tolerance tests 
(ITT, week 11) for glucose levels measured up to 120 min post glucose or insulin injection, as depicted in 
Figures 3.12 and 3.13, respectively. All data is presented as mean  SEM, n = 6-8 per treatment group. 
 
 
3.3.2.2.2 Fasting blood glucose levels 
No significant difference in fasting blood glucose levels was observed between mice of 
any treatment group at week 10 of the experiment (Table 3.2).  
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3.3.2.2.3 Glucose and insulin tolerance tests 
No significant differences in blood glucose levels were observed in mice of any 
treatment during the GTT (Figure 3.11) or ITT (Figure 3.12). Similarly, no differences 
observed in the area under the curve of the GTT or ITT (Table 3.2). 
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 Figure 3.11: Glucose tolerance tests (GTT). 
UCP-1 luciferase transgenic mice were fed a 
low fat diet (LFD) for 4 weeks of age until 8 
weeks of age. Mice were then separated 
into one of the four treatment groups, in 
which mice were: 1. fed the LFD; 2. fed a 
high fat diet (HFD); 3. fed a HFD with 
ongoing ultraviolet radiation (UVR) exposure 
twice a week; or, 4. fed a HFD with ongoing 
UVR exposure twice a week followed by 
immediate topical treatment of exposed 
skin with cPTIO (0.1mmol, UVR + cPTIO), for 
12 weeks. The GTT was conducted after 10 
weeks of the treatments, with results 
comparing data for (a) all treatment groups, 
(b) mice fed a LFD or HFD, (c) mice fed a 
HFD with or without ongoing UVR exposure, 
and (d) for mice fed HFD with ongoing UVR 
exposure with or without topical treatment 
with cPTIO. Data are presented as mean  


















































































































Figure 3.12: Insulin tolerance test (ITT). 
UCP-1 luciferase transgenic mice were fed 
a low fat diet (LFD) for 4 weeks of age 
until 8 weeks of age. Mice were then 
separated into one of the four treatment 
groups, in which mice were: 1. fed the LFD; 
2. fed a high fat diet (HFD); 3. fed a HFD 
with ongoing ultraviolet radiation (UVR) 
exposure twice a week; or, 4. fed a HFD 
with ongoing UVR exposure twice a week 
followed by immediate topical treatment 
of exposed skin with cPTIO (0.1mmol, UVR 
+ cPTIO), for 12 weeks. The ITT was 
conducted after 11 weeks of the 
treatments, with results comparing data 
for (a) all treatment groups, (b) mice fed a 
LFD or HFD, (c) mice fed a HFD with or 
without ongoing UVR exposure, and (d) for 
mice fed HFD with ongoing UVR exposure 
with or without topical treatment with 
cPTIO. Data are presented as mean  SEM 
(n=8 per treatment). 
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3.3.2.4 Summary: Measures of NAFLD and type-2 diabetes  
Mice fed a high fat diet with ongoing UVR exposure had reduced liver 
histopathological scores compared to mice fed a high fat diet (only) and mice with 
ongoing UVR exposure followed by cPTIO administration. Mice fed a low fat diet also 
had a reduced histopathological scores compared to mice fed a high fat diet. No 
significant differences liver weights between mice of different treatment groups were 
observed. No signs of type-2 diabetes (e.g. elevated fasting glucose or insulin levels in 
blood, or signs of glucose intolerance or insulin resistance) were observed in mice fed a 
high fat diet.  
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3.4 Summary of main findings 
 
3.4.1 Circadian studies  
No significant cosinor rhythms in UCP-1 expression in iBAT or interscapular skin 
temperatures or blood glucose were observed when circadian studies were done at 
baseline, week 6 and week 12 of the experiment. Mice fed a high fat diet had 
significantly increased UCP-1 levels in iBAT at ZT1, 3, 5, 13, 17, 23 and 27 throughout 
the 28 hours, compared to mice fed a low fat diet. Mice fed a high fat diet with ongoing 
UVR exposure had reduced UCP-1 expression in iBAT, compared to mice fed a high fat 
diet at ZT27 at week 12. There was no difference in UCP-1 expression in mice fed a 
high fat diet exposed to UVR with or without cPTIO treatment. 
 
Mice fed a high fat diet had increased blood glucose at several timepoints during the 
circadian studies done at weeks 6 and 12. No difference was observed in mice fed high 
fat diet with or without cPTIO, when compared to each other or with mice fed a high fat 
diet when comparing the blood glucose.  
 
Mice administered with cPTIO with ongoing UVR exposure had increased interscapular 
skin temperature at ZT1 9 and 23 compared to mice with ongoing UVR exposure 
without cPTIO treatment. Interestingly, mice fed a high fat diet had increased 
interscapular skin temperature at ZT13 at week6, compared to mice fed a low fat diet. 
Additionally, mice fed high fat diet and mice with cPTIO administration also had 




3.4.2 Metabolic outcomes  
The major findings of the effects of low dose UVR on signs of adiposity, NAFLD and 
type-2 diabetes in UCP-1 luciferase mice fed a high fat diet are described in the table 
below (Table 3.3). UVR suppressed gWAT weights, iBAT weights and liver 
histopathology scores, with the effects of UVR on liver histopathology reversed by 
subsequent treatment with the nitric oxide scavenger, cPTIO (Table 3.3). 
 
Table 3.3: Metabolic outcomes summarised.  
Metabolic Outcomes 
Outcome LFD1 HFD UVR UVR + cPTIO 
Body weight Reduced Increased* NS NS 
Weight gain Reduced Increased* NS NS 
gWAT weight Reduced Increased* Reduced# NS 
iBAT weight Reduced Increased* Reduced# NS 
Liver histopathology score Reduced Increased* Reduced#  Increased^ 
1In this experiment, UCP-1 luciferase transgenic mice were treated with 1 of 4 treatments in 
which mice were: 1. fed the LFD; 2. fed a high fat diet (HFD); 3. fed a HFD with ongoing 
ultraviolet radiation (UVR) exposure twice a week; or, 4. fed a HFD with ongoing UVR exposure 
twice a week followed by immediate topical treatment of exposed skin with cPTIO (0.1mmol, 
UVR + cPTIO), for 12 weeks. *p<0.05 HFD v LFD, # p<0.05 HFD v UVR, and ^p<0.05 UVR v 












Obesity and metabolic dysfunction are a major risk factor for mortality and reduced life 
expectancy(2,3). Obesity is commonly thought to occur when there is an imbalance 
between energy intake and expenditure. Lifestyle interventions of increasing physical 
activity and eating low caloric diets are commonly used to treat obesity(33,46,52). 
However, the long-term efficacy of these interventions is limited(36,262,382). In this 
study, we focused on another factor, which may modulate the development of obesity 
and metabolic dysfunction, sun-derived UVR(1,102). Inadequate sun exposure may 
arise when individuals spend reduced time outdoors, engaging in sedentary indoor 
pursuits (e.g. increased screen time)(325,345). There is modest evidence from human 
studies that sun exposure has cardiometabolic protective effects(383,384). Findings 
from our laboratory have demonstrated that ongoing exposure to low dose (non-
burning) UVR suppressed signs of obesity and type-2 diabetes in mice fed a high fat 
diet (partially) through release of nitric oxide from skin(1,102). Disruptions in circadian 
rhythm may also contribute to the development of obesity and metabolic dysfunction, as 
observed in people who undertake shift work (9,247,264,280,297). Many metabolic 
functions are under circadian control, including energy intake, expenditure and 
homeostasis, as well as adipose tissue physiology(9,262). There are circadian rhythms 
in thermogenesis processes in BAT(9,310,399). Nitric oxide may enhance 
mitochondrial biogenesis and thermogenesis in BAT (390).  We hypothesized that UVR 
would alter the circadian rhythm of thermogenesis in iBAT of mice fed a high fat diet, 
through the release of nitric oxide bioactivity from skin.  
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4.2 Key findings 
In the circadian studies, UCP-1 levels in iBAT modestly increased with time in mice fed 
a low fat diet when comparing levels measured throughout the 28 h time-courses done 
at baseline and after 6 and 12 weeks.. All mice fed a high fat diet had increased UCP-1 
levels iBAT in week 12, compared to week 1 and week 6, and when compared to mice 
fed a low fat diet. There were only limited effects of exposure to UVR on UCP-1 levels 
in iBAT, where mice exposed to UVR had reduced UCP-1 levels only at ZT27 in week 
12 of the study. No significant cosinor (circadian) rhythms were observed in UCP-1 
levels in iBAT, blood glucose and interscapular skin temperature at any time point 
(weeks 0, 6 or 12) for mice of UVR and any other treatment (Table 3.1, see section 
4.3.2). Mice exposed to low dose UVR had reduced signs of adiposity, including 
reduced gonadal WAT and iBAT weights, and hepatic steatosis, compared to mice fed a 
high fat diet only. The reduction in hepatic steatosis in mice exposed to ongoing UVR 
was dependent on the skin release of nitric oxide, as skin treatment with the nitric oxide 
scavenger, cPTIO, reversed the suppressive effects of UVR on histopathological signs 
of hepatic steatosis. These key findings (and others) are discussed in detail below.  
 
4.2.1 Circadian rhythm of thermogenesis in iBAT, skin temperature and 
blood glucose 
 
4.2.1.1 UCP-1 and thermogenesis in interscapular brown adipose tissue 
Mice fed a low fat diet had significantly increased levels of UCP-1 in iBAT when 
measured throughout the study at weeks 6 and 12 compared to baseline (from 
5.831.39x103 at week 0 to 12.51.64x103 at week 12, meanSEM). This was 
supported by findings from our previous study in which UCP-1 levels (from 7.230.79 
x103 at week 0 to 10.362.00x103 at week 12; UCP-1 radiance meanSEM) in UCP-1 
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transgenic mice fed the same low fat diet(389) However, this increase in UCP-1 levels 
in iBAT measured at 12 weeks was significantly lower than the increase detected in 
mice fed a high fat diet (Figure 3.1).. Indeed, in mice fed a high fat diet (only) there was 
~2-fold increase on average throughout the day in UCP-1 levels in iBAT by week 12, 
compared to mice fed the low fat diet. These differences in UCP-1 expression in iBAT 
were observed at week 12 at ZT1, ZT3, ZT13-27. This increase in UCP-1 expression in 
iBAT may have been caused by increased uptake of circulating FFA that resulted from 
mice eating the high fat diet, inducing uncoupled respiration (diet-induced 
thermogenesis) in the mitochondria of brown adipocytes(58,245,400). Indeed chronic 
high fat diet may increase the capacity for BAT to use FFA, possibly via mitochondrial 
alteration(401).  
 
Except for one time point, we did not observe significant effects of exposure to UVR on 
on UCP-1 expression in iBAT compared to mice fed a high fat diet, confirming our 
previous findings(389). The current study was done due to concerns that we may missed 
more subtle effects of low dose UVR by not accounting for the biorhythm of UCP-1 in 
iBAT, and previously measured UCP-1 levels in iBAT at a time between 10am and 2 
pm (ZT5 to ZT9)(389).. We did observe a reduction in UCP-1 levels in iBAT at Z27 (at 
the 12 week time point), 24 hours after UVR was administered (compared to levels 
measured in mice fed a high fat diet). Diet-induced thermogenesis is hypothesised to be 
a compensatory and protective response to buffer metabolic dysfunction that occurs 
during chronically increased energy intake (402). We hypothesise that this reduction in 
UCP-1 levels in iBAT 24 hours post-UVR may be an indirect response of earlier effects 
of UVR exposure on other metabolic outcomes (e.g. reduced FFAs levels), whereby 
reduced UCP-1 levels in iBAT reflect a reduced requirement for diet-induced 
thermogenesis in mice fed the high fat diet. Further studies are needed to characterise 
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the effects of exposure to low dose UVR on circulating FFA levels. There was no 
significant difference in UCP-1 expression in the iBAT of mice exposed to UVR, with 
or without topical cPTIO, suggesting this effect of UVR in UCP-1 expression in iBAT 
was not dependent on skin release of nitric oxide.When mice were administered with a 
nitric oxide donor, a reduction in UCP-1 level was observed by Dhamrait et al (2017), 
which is consistent with this study. Indeed, smaller deposits of gonadal WAT and iBAT 
in mice exposed to UVR may indicate a reduced need for diet-induced thermogenesis 
(Figure 3.6 and 3.7).  
 
4.2.1.2 Interscapular skin temperature  
Interscapular skin temperature may be a good surrogate for iBAT activity in 
humans(10,245,403) although studies in mice are limited. In the present study, mice fed 
a high fat diet had a significantly increased interscapular skin temperature compared to 
mice fed low fat diet (week 6, ZT13 and ZT27: week 12, ZT23). Findings of van der 
Berg et al. (2018), who observed a peak of UCP-1 expression and thus heat release from 
iBAT at the onset of dark phase(246), which occurs at ZT13. However, we observed no 
significant difference in the UCP-1 level in iBAT at this time. At week 6 (ZT27) and at 
week 12 (ZT23) an increase in both interscapular skin temperature and UCP-1 was 
observed in mice fed a high fat diet compared to mice fed low fat diet. A positive 
association between interscapular skin temperature and UCP-1 levels at week 6 is 
consistent with human studies(245).  
 
At week 6 (Z13), mice fed high fat diet with ongoing UVR exposure had reduced 
interscapular skin temperature compared to mice fed high fat diet or those also treated 
with cPTIO (Figure 3.3b). Similarly, in week 12 of the experiment, mice fed high fat 
diet administered cPTIO after UVR exposure had increased interscapular skin 
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temperature compared to mice exposed to UVR (only) at ZT1, ZT9 and ZT23. Since 
there was no difference in UCP-1 levels between mice with ongoing UVR with or 
without cPTIO at these times, UV-induced nitric oxide may modify skin temperature 
independently of UCP-1 expression in iBAT at these times(359,390,404). There could 
be other factors that modulate localised skin temperatures differences throughout the 
day, including other metabolites from the nitrate-nitrite-nitric oxide pathway, fur of the 
mice and housing temperatures.  
  
A trend (p=0.06) for a cosinor rhythm in the interscapular skin temperature was 
observed at week 12 in mice of two treatments (mice fed a high fat diet (only), and mice 
fed a high fat diet with ongoing UVR exposure and cPTIO administration; Table 3.1 
Earlier studies have similarly observed cosinor rhythmicity in skin temperature 
throughout the day (without any alteration to diet) in healthy humans(405).  
 
4.2.1.3 Blood glucose 
No significant differences in the blood glucose levels of mice in any of the treatment 
groups were observed at baseline timepoint. Mice fed a high fat diet had significantly 
increased blood glucose levels compared to mice fed a low fat diet at week 6 (ZT5 and 
ZT9) and week 12 (ZT5, ZT9, ZT17-27). The increased blood glucose levels in mice 
fed a high fat diet are consistent with literature for mice of the FVB/NJ 
strain(1,102,406-408). Mice, being nocturnal, feed and are active during the dark phase 
of the photoperiod(258,309,315), which may explain the augmentation of blood glucose 
levels in mice fed a low fat diet at Z13, at all times. The dawn phenomenon of 
increasing blood glucose upon awakening (with the body preparing the start of the ‘day’ 
with maximum energy)(317) was not observed in any mice fed a high fat diet. 
Hyperglycaemia maintained throughout the day by eating a high fat diet eliminates the 
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need for the dawn phenomenon(88,314). Meanwhile, altered feeding pattern due to 
chronodisruption throughout the 28 hours could be a plausible reason for the lack of a 
circadian rhythm entrainment and this could also alter the blood glucose levels 
(discussed further in study limitations)(9,306). Interestingly, UVR exposure had no 
effect on the blood glucose levels in mice fed a high fat diet. These are similar findings 
to our other studies where UVR did not have any effect on the fasting blood glucose 
levels in UCP-1 luciferase transgenic mice fed a high fat diet(102,389), but different to 
the suppression of glucose intolerance observed in C57Bl/6J mice fed a high fat diet (1). 
The reduced ability for mice of the FVB/NJ background to gain weight and display 
signs of impaired glucose metabolism may explain the lack of effect of UVR on blood 
glucose levels in the current study.  
 
4.2.2 Signs of adiposity induced by high fat diet 
 
4.2.2.1 Body weight and weight gain 
Mice fed a high fat diet had significantly greater body weights and weight gain 
compared to mice fed a low fat diet from week 1 until the end of the study. These 
findings were consistent with our previous findings examining the effects of a high fat 
diet on adiposity in UCP-1 luciferase transgenic male mice (FVB/NJ background)(389) 
and C57Bl/6 mice(1,102). There was no significant effect of ongoing UVR exposure on 
body weights or weight gains in mice fed a high fat diet with ongoing throughout the 12 
weeks (Figure 3.4). This was consistent with our previous study performed in the same 
mouse strain (UCP-1 luciferase transgenic mice) where these mice were housed as 
groups(389). We have previously observed that ongoing exposure to low dose UVR 
significantly reduced weight gain in C57Bl/6J mice fed a high fat diet(1,102). This 
inconsistency may be due to the differing responses to eating a high fat diet between the 
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two strains of mice, since mice of the FVB/NJ strain are more resistant to diet-induced 
obesity in terms of body weight and weight gain compared to C57Bl/6 mice(409,410). 
Of particular note are the reduced body weights and weight gains for all mice observed 
at week 7 and end of the study, compared to the previous week. This reduction in the 
body weight and weight gain was likely caused by the he intense circadian studies 
carried out in the week prior on these mice. Circadian studies required mice to be bled 
(for blood glucose levels) and be under anaesthesia for a long period of time over 28 
hours due to the UCP-1 measurements done via IVIS spectrum bioimager.  
 
4.2.2.2 Gonadal white adipose tissue weights 
Mice fed a high fat diet had an increased gonadal WAT mass compared to mice fed a 
low fat diet (Figure 3.7). This finding is consistent with studies conducted in both 
FVB/NJ(407,411) and C57Bl/6(102,412) mice. Some findings suggest that the rate of 
adipocyte cell size growth is independent of strain and that gonadal WAT weights were 
more strongly linked with diet when the effects of eating a high fat diet were compared 
in C57Bl/6 and FVB/NJ mice(408). Other studies suggest that mice of the wildtype 
FVB/NJ strain have increased gonadal WAT deposits compared to mice of the C57Bl/6 
mice strain in response to eating a diet with fat content (5% fat) similar to the low fat 
diet used in our studies (5% fat), which could explain our findings, and suggest that 
lipid deposition depends upon the mouse strain rather than the diet(411).  
 
In the current study, mice fed a high fat diet had increased gonadal WAT mass 
compared to mice fed a high fat diet with ongoing UVR exposure (Figure 3.7). This 
suggests that ongoing UVR exposure could suppress the additional accumulation of 
white adipocytes in iBAT, induced by the high fat diet as described in other 
studies(190,414,415). We have not previously observed this effect of low dose UVR in 
 101
C57Bl/6 mice fed a high fat diet(1,102), in which there was no significant difference in 
gonadal WAT tissue weights despite reduced body weights and weight gain in mice fed 
a high fat diet with ongoing UVR exposure. It may be that ongoing exposure to UVR 
suppressed the accumulation of lipids in white adipocytes in abdominal region of UCP-
1 luciferase transgenic mice(411). The FVB/NJ mouse strain is more prone to 
accumulating WAT in the gonadal region compared to C57Bl/6 mice(411). Since there 
was no difference in gonadal WAT deposits sizes between mice with ongoing UVR 
exposure with or without topical cPTIO treatment, the reduction gonadal WAT levels 
induced by exposure UVR was independent of nitric oxide (Figure 3.7).  
 
4.2.2.3 Interscapular brown adipose tissue weights 
Mice fed a high fat diet had increased iBAT weights compared to mice fed a low fat 
diet, and, mice fed a high fat diet exposed to UVR (Figure 3.8). This finding is 
consistent with recent studies, in which SV129(413) or FVB/N(407,408) mice fed a 
high fat diet had significantly increased iBAT weights when compared to mice fed a 
low fat diet. We have also previously observed that ongoing exposure to low dose UVR 
reduced iBAT deposit size in C57Bl/6J mice fed a high fat diet(102). These data suggest 
that the ongoing exposure to low dose UVR may suppress the deposition of WAT 
within iBAT deposits. Topical application of cPTIO (nitric oxide scavenger) did not 
significantly reverse the effects of low dose UVR on the size of iBAT deposits, 
suggesting that these effects were largely independent of skin release of nitric oxide.  
 
4.2.3 Signs of non-alcoholic fatty liver diseases 
Mice fed a low fat diet and mice fed a high fat diet with ongoing UVR exposure had 
significantly reduced histopathological signs of NAFLD, particularly hepatic steatosis, 
compared to mice fed a high fat only (Figures 3.10 and 3.11). Moreover, consistent with 
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our previous studies(1,102,389), the nitric oxide scavenger cPTIO suppressed these 
beneficial effects of UVR (Figures 3.10 and 3.11), suggesting that the pathway 
responsible for these benefits occurs through release of nitric oxide from skin. These 
findings were also consistent with other studies that observed reduced hepatocyte 
apoptosis from ongoing exposure to 12 h/day UVR of Lewis rats fed a choline-deficient 
iron-supplement L-amino acid-defined diet (used to induce NASH)(388); although, the 
actual dose and spectrum of UVR received by these rats is unclear. Similarly, the 
benefits of nitric oxide metabolites for preventing signs of NAFLD were observed in a 
study of male Swiss-Kunming mice supplemented with inorganic nitrate-enriched 
spinach (60 mg nitrate/kg for 28 days), which prevented cellular degeneration and 
hepatocyte necrosis resulting from eating a high fat and fructose diet(416). In humans, 
exposure to UVA radiation increased the plasma nitrate levels and reduced blood 
pressure in 24 healthy young male adults from the UK, independently of nitric oxide 
synthase (NOS) activity(354), but increased circulating nitrite levels, and was 
associated with increased skin nitric oxide levels(354). Protection from hepatic steatosis 
may be induced by exposure to low dose UVR through the released of nitric oxide 
bioactivity(394) from the skin to the circulation, which may be transported to the liver 
via circulation, although further experiments are needed to confirm this hypothesis. The 
skin released nitric oxide mimics the eNOS pathway, where eNOS derived nitric oxide 
acts on the liver sinusoidal endothelial cells, which further inhibit the inflammatory 
activation of Kupffer cells (resident liver macrophages)(393). It is only through eNOS 
or NO donors that the protective effect is observed, since iNOS derived nitric oxide is 
generally pathological, since it can facilitate formation of free radicals(393). Future 
studies should be aimed towards human translation of this knowledge and determine 
how this eNOS derived nitric oxide could be maximised for beneficial advantage in 
humans with NAFLD. 
 103
 
4.2.3.1 Liver weights 
Mice fed a high fat diet did not have significantly increased liver weights compared to 
mice fed a low fat diet (Figure 3.9). This was an unexpected result as in many studies, 
increases in liver weight have been observed in mice fed a high fat diet, due to lipid 
deposition in the liver(54,417,418). However, there are inconsistencies in the effects of 
high fat diet on liver weight, with varying responses between mice of differing strains, 
fed diets with diverging fat contents(419). For example, in our previous studies, we 
observed that C57Bl/6J mice fed a high fat diet had increased liver weights compared to 
mice fed a low fat diet(1,102). However, in a similar study done in our laboratory using 
the UCP-1 luciferase transgenic mice, there was no significant difference in liver 
weights in mice fed a low or high fat diet(389). Some studies suggest that loss in liver 
weight in mice fed a high fat diet could be due to reduced capacity to retain water(420).  
 
4.2.3 Glucose and insulin metabolism 
No significant signs of type-2 diabetes (fasting blood glucose levels, fasting plasma 
insulin levels, GTT and ITT) were observed in mice fed a high fat diet in this study. 
This was an unexpected finding as previous studies have established signs of type-2 
diabetes in a similar model in C57Bl/6 mice(1,102). In our previous study done in UCP-
1 transgenic male mice, significantly elevated fasting blood glucose levels, glucose 
intolerance and insulin resistance were observed in mice fed a high fat diet compared to 
mice fed a low fat diet(389). We also observed a protective effect of UVR in limiting 
signs of glucose intolerance and insulin resistance in these UCP-1 luciferase transgenic 
mice fed a high fat diet(389). The results of the current study could be explained in 
terms of housing as the mice in current study were housed individually, compared to 
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group housing of our previous studies, which elicits more stress compared to previous 
studies with grouped housing(421).  
 
4.3 Study limitations 
Below we discuss some limitations of this study. 
 
4.3.1 Circadian analyses 
Performing the circadian analyses may have disrupted the sleep-wake and feeding 
patterns of the experimental mice used in this study(5). Transporting mice from the 
housing room during the dark phase exposes them to some blue light, although every 
effort was made to limit exposure. However, it was not possible to inject mice 
intraperitoneally with luciferin in dark conditions. We also observed some negative 
effects of performing these circadian measurements on body weight, with mice 
experiencing transient weight loss in the week after these were completed (Figure 3.4, 
3.6). This weight loss was likely caused by the stress of the frequent anaesthetic events 
(each 20 min in length), intraperitoneal injections, blood acquisition and animal 
handling requirements of each 28 hours cycle of measurements. One advantage of our 
circadian studies was that we were able to quantify the effects of ongoing UVR 
exposure in the same mice, at baseline, 6 and 12 weeks, limiting the number of animals 
required, and allowing continuous measures to be recorded in individual animals.  
 
4.3.2 Mice strain 
The FVB/NJ mice strain is extensively used for the generation of transgenic animals 
such as UCP-1 luciferase transgenic mice(215,422). However, the FVB/NJ strain of 
mouse exhibits specific traits that are a limitation when used in studies of behaviour and 
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circadian rhythm(422). Mice of the FVB/NJ genetic background express a retinal 
degeneration (rd) mutation in the rhodopsin gene, which impairs the network of 
photoreceptors in the eyes(422,423). While blind to visual images, FVB/NJ mice are 
still capable of maintaining a regular metabolic circadian rhythm in response to blue 
light(422). However, this visual impairment may interfere with the establishment of 
normal circadian rhythms in mice of the FVB/NJ mice, which exhibit increased activity 
during the light phase, and a disrupted sleep-wake cycle and affects natural spontaneous 
behaviours such as aggression and fighting behaviour(422). This lack of circadian 
entrainment is a limitation when using a transgenic mouse with FVB/NJ genetic 
background to study circadian biology (see Section 4.3.2). However, the UCP-1 
luciferase transgenic mice are only available on the FVB/NJ genetic background. It 
would be more ideal to produce transgenic mice on a different genetic background (e.g. 
C57Bl/6J) for the future studies of circadian rhythm and metabolism(215). Moreover, 
the FVB/NJ strain background mice are less susceptible to obesity and type-2 diabetes 
development when fed a high fat diet, compared to other strains especially C57Bl/6, 
mice, such that FVB/NJ may be a less optimal model animal for studying obesity and 
type-2 diabetes(75,79,426).  
 
4.3.3 Housing  
The mice used in this study were bred and housed in the same facility with many 
environmental factors controlled including lighting, air quality, housing and enrichment. 
Mice were kept at 22.2  1.6 ºC (mean  SD), temperatures below thermoneutrality for 
mice, which means that mice in these studies may have experienced constant mild to 
moderate cold stress(217,427). Mice were provided with bedding, tissues and PVC 
piping to allow the singly housed mice overcome any thermal stress. Speakman (2013) 
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suggests that mice housed as singletons require optimum thermoneutral temperatures 
ranging from 23-25C(427). However, other studies suggest that  thermoneutrality in 
mice occurs at 30-32C(208), while sub-thermoneutrality occurs between 20-
26C(208). We have previously observed significant aggressive behaviour between co-
housed UCP-1 luciferase transgenic mice(389), and upon commencing this study, new 
ethical requirements were introduced to house these mice individually to avoid the 
aggressive behaviour leading to adverse outcomes.  
 
4.3.4 Translation to humans 
It will be important to demonstrate that the findings observed in these experimental 
mouse studies can be translated clinically or in public health settings. Similar animal 
models to those described here are used widely, with obvious benefits around 
controlling food intake, diet, outdoor activity and sun exposure. However, there may be 
limitations for applying our findings in mice to humans as due to species differences. 
Indeed, unlike humans, mice are nocturnal and usually consume food during the dark 
phases(428). By contrast, humans tend to eat three to four meals during the light phase 
of the day(428). There are variations in mouse and human skin composition as well. 
Human skin has thicker epidermal, dermal and hypodermal (subcutaneous fat) layers 
compared to mouse, which have more densely packed hair follicles compared to human 
skin(429). Thicker dermal layers increase the amount of nitric oxide released from UVR 
exposed human skin (compared to mice), increasing the potential for this pathway to 
influence metabolic function in people. Further work is needed to demonstrate whether 
the metabolic benefits of exposure to UVR observed in these mouse studies can also be 
detected in humans, which could be done through clinical trials and cell culture studies.  
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4.4 Directions for future research 
Future studies could be focused on clinical trials and cells culture studies to determine 
the effect of nitric oxide on BAT size and functionality in humans. More research is 
required to appropriately quantify the effects of ongoing exposure to safe levels of UVR 
and/or sunlight on the development on obesity and type-2 diabetes, focusing on the roel 
of BAT. Furthermore, studies in humans focusing on the circadian rhythm of BAT 
activity would establish the nature of BAT activity to determine the pathways to 
activate BAT activity to suppress the development of obesity. Future studies could also 
focus on BAT activity and this reduces with aging in humans(58,236,250) and if the 
same phenomenon is seen in rodents. Future circadian studies could focus on the 
glucose and FFA uptake levels(224,230,232) and the effect UVR might have on the 
uptake levels to best help curb the development of metabolic dysfunction. It would be 
fascinating to examine the relationship between UCP-1 expression and the FFA and 
glucose uptake in humans and the effects of UVR on uncoupled respiration.  
 
4.5 Conclusion  
Consistent with previous research(1,102), this investigation demonstrated that UVR and 
UVR-induced nitric oxide may have significant health benefits in suppressing signs of 
NAFLD, and adiposity. Furthermore, we observed that ongoing exposure to UVR had 
modest effects on signs of thermogenesis in iBAT of mice fed a high fat diet. Mice fed a 
high fat diet with ongoing UVR exposure had reduced UCP-1 levels 24 hours post UVR 
exposure; suggesting that UVR exposure helps in buffering the metabolic function in a 
better way. Ongoing UVR exposure may lower the need for thermogenesis in mice fed a 
high fat diet with reduced amount of UCP-1 radiance in iBAT and interscapular skin 
temperatures observed in irradiated mice at certain times of the day. Low dose UVR 
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also reduced signs of adiposity (e.g. gonadal WAT weights, hepatic steatosis). 
However, there were no effects of eating a high fat diet on signs of type-2 diabetes. Our 
observations suggest that the effects of low dose UVR in reducing signs of adiposity 
were not due to enhanced thermogenesis in iBAT. Some of the effects of ongoing UVR 
exposure were dependent on skin release of nitric oxide dependent such as the reduction 
of signs of NAFLD. This research adds further evidence to support and the hypothesis 
that UVR and its effector molecules, such as nitric oxide, may have beneficial effects on 
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